Trading Analysis Report: META¶

Generated: 2026-10-02 10:46:23

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 725.93 Price As Of: 2026-10-01

META (Meta Platforms, Inc.) Technical Report, as of 2026-10-01¶

The OHLCV figures, the 10 EMA, 50/200 SMA, Bollinger levels, MACD (line, signal and histogram), RSI and ATR are the verified snapshot values. The separate indicator calls for RSI, MACD and ATR matched the snapshot exactly, so I found no discrepancies. The ADX, OBV, SuperTrend, TD-9 and Z-Score values come from the indicator tools and are not in the snapshot.

1. Indicators chosen and why¶

Role	Indicator	Why it suits META now
Trend (multi-timeframe)	supertrend	The stock has moved from about 540 to about 726, so I need the trend regime and stop distances on weekly, monthly and daily bars.
Trend strength	adx	It shows whether the September surge is still a strong trend or is fading into a range.
Momentum	macd	The MACD line, signal and histogram show momentum peaking and cooling.
Momentum / overbought	rsi	RSI hit 80 last week and has since reset, so it shows how much of the overbought condition has cleared.
Volatility / risk	atr	The September gap expanded volatility, so ATR is needed for stop and position sizing.
Volume	obv	It checks whether volume supports the rally or diverges from price.
Exhaustion	td_9	It flags whether the move is nearing a DeMark exhaustion point.
Stretch	z_score	It measures how far price has moved from its mean on each timeframe.

I also used the snapshot's 10 EMA, 50 SMA, 200 SMA and Bollinger bands for structure.

2. Price action¶

Sept rally. META closed at 545.40 on 2026-08-20 and 725.93 on 2026-10-01, up about 33% over roughly six weeks. It dipped to a 524.08 low on 2026-07-30 (close 538.60) and has risen about 35% from that close.
Gap day. On 2026-09-21 the stock closed at 741.25, up from 665.23 the prior close, a gain of about 11.4%. Volume was 48.7M, the heaviest in the data window apart from 2026-04-30 (52.8M) and 2026-07-01 (45.5M). I did not see the cause in the tool output, so I can't say what drove it.
Peak. The highest close was 777.59 on 2026-09-24, with an intraday high of 779.82. Price then pulled back, closing at 751.66 on 09-25 and 715.62 on 09-28. The 09-28 session was a high-volume down day (27.9M) with a low of 713.19.
Last three sessions. Closes were 738.79 (09-29), 725.18 (09-30) and 725.93 (10-01). The stock is consolidating about 6.6% below the peak close, and 10-01 volume of 12.4M was the lowest of September. That points to a quiet pause, not heavy selling.
Moving averages. Price is above the 10 EMA (721.70), narrowly, and well above the 50 SMA (622.21) and 200 SMA (626.98). The 50 SMA is still below the 200 SMA, by about 4.8 points. A golden cross is therefore close but has not happened. At the current pace of the rally it could be approaching, but I can't confirm a date.

3. Trend (supertrend and ADX)¶

SuperTrend is up on all three timeframes.
Weekly (primary): up, stop 563.23, close 28.89% above it.
Monthly: up, stop 522.45, close 38.95% above it.
Daily: up, stop 680.67, close 6.65% above it.
The higher timeframes outrank the daily, and all agree, so the primary trend is bullish. The weekly and monthly stops are too far away to be useful for tactical risk. The daily stop at 680.67 is the closest trend-based risk level.
ADX is 45.61, well above the 25 threshold for a tradable trend. It was only 6.8 to 7.4 in early September. It peaked at 64.10 on 09-25 and has dropped for four straight sessions (56.96, 51.86, 48.21, 45.61). Readings above 60 are unusually strong. The decline means trend strength is fading as price consolidates, which is normal after a surge. It does not signal a reversal. I did not pull +DI and -DI, so the direction comes from price and SuperTrend.

4. Momentum (MACD and RSI)¶

MACD is 36.17 against a signal of 35.38, so the histogram is only +0.80. The line peaked at 42.93 on 09-25 and has declined each session since, from 40.51 on 09-28 to 40.01, 38.06 and 36.17. The line is still well above zero, which is bullish, but a bearish signal-line cross is close. A histogram turning negative would confirm that momentum is cooling.
RSI is 61.15. It reached 80.55 on 09-24, the overbought extreme, and fell to 61.0 by 09-28. It has since stayed at 61 to 64.6 (64.56 on 09-29, 61.03 on 09-30). RSI above 80 followed by a reset to the low 60s without a price collapse is consistent with a healthy trend digesting gains. It is not oversold, so there is no mean-reversion buy signal here.

5. Volatility (ATR and Bollinger)¶

ATR is 26.18. It was about 20 to 21 through mid-September and jumped to 25.97 on the 09-21 gap day. That is roughly 3.6% of price per day. As a derived sizing rule, a 2×ATR stop is about 52 points, or around 673.6 from the current close. That sits just below the daily SuperTrend stop (680.67).
Bollinger bands: lower 587.38, middle 689.77, upper 792.15. The bands are wide after the surge. Price sits between the middle and upper bands and is nowhere near the upper band. The middle band (689.77) is a possible pullback reference, but I have no evidence in this data of it acting as support before.

6. Volume (OBV)¶

OBV is 465.25M. It rose from 307.1M on 09-01 to a peak of 502.3M on 09-24, which matched the price peak on 09-24.
It then fell to 448.6M on 09-28 and has partly recovered (472.2M on 09-29, 452.9M on 09-30, 465.3M on 10-01).
There is no clear divergence. OBV peaked on the same day as price and has pulled back in line with it. The September rally had strong volume behind it. OBV falling below its early-September trend would be a warning sign.

7. Exhaustion and stretch (TD-9 and Z-Score)¶

TD-9 counts are weekly -6 (sell setup, 6 of 9), monthly -2 (sell setup, 2 of 9) and daily +4 (buy setup, 4 of 9). The weekly count has three more weeks to reach 9 if the pattern holds, so weekly exhaustion is approaching but not complete. The daily +4 reflects the recent pullback and is not a buy signal. The higher timeframe carries more weight, so the signal leans toward a late-stage advance.
Z-Score is weekly +2.00, monthly +1.05 and daily +0.71. The weekly reading is at the threshold for a statistically stretched price, which is a mean-reversion watch. The daily reading shows the recent consolidation has brought price back close to its 20-day mean. In a strong trend (ADX 45.6, all SuperTrends up) a high weekly z-score can persist, so I would not fade it on its own.

8. Reference levels (from the tool data only)¶

Overhead: 744.10 (09-23 close), 751.66 (09-25 close), 777.59 (peak close, 09-24) and 779.82 (peak intraday high).
Nearby support: 721.70 (10 EMA), 713.19 (09-28 low), 689.77 (Bollinger middle) and 680.67 (daily SuperTrend stop).
Deeper support: 665.23 (09-18 close, pre-gap), then the 50 and 200 SMAs at 622.21 and 626.98.
I did not verify any historical bounces at these levels, so treat them as reference points only.

9. Overall read for the decision-maker¶

Primary trend: bullish on all three SuperTrend timeframes, with price far above the 50 and 200 SMAs.
Short-term: consolidating after a spike, with cooling momentum (MACD histogram near zero, RSI reset from 80 to 61, ADX falling from 64 to 46).
Risks:
The weekly z-score is at +2.00 and the weekly TD-9 count is at 6, which suggest a late-stage advance.
A bearish MACD cross looks near.
A daily close below the 10 EMA and the 713.19 low would weaken the short-term setup.
A daily close below 680.67 would flip the daily SuperTrend.
Supportive factors: OBV confirms the rally, ADX is still above 25, and volume dried up on the pullback.
Positioning: the evidence favors holding existing exposure with stops sized by ATR. For new entries, a pullback toward the 10 EMA or the Bollinger middle band looks better than chasing near the highs. This is my reading of the data, and the final trade decision is for the next agent.

Summary table¶

Item	Value (2026-10-01 unless noted)	Interpretation
Close	725.93 (OHLC 728.53 / 735.88 / 721.51, volume 12.38M)	Quiet consolidation, lowest volume of September
Peak close / intraday high	777.59 (09-24) / 779.82	Close is about 6.6% below the peak close
10 EMA / 50 SMA / 200 SMA	721.70 / 622.21 / 626.98	Price above all three; 50 SMA still below 200 SMA
Bollinger lower / mid / upper	587.38 / 689.77 / 792.15	Price in the upper half, not at the band
SuperTrend weekly / monthly / daily	Up, 563.23 / Up, 522.45 / Up, 680.67	Bullish on all timeframes; daily stop is 6.65% below price
ADX	45.61 (peak 64.10 on 09-25)	Strong but fading trend
MACD / signal / histogram	36.17 / 35.38 / +0.80	Momentum cooling; bearish cross close
RSI	61.15 (peak 80.55 on 09-24)	Reset from overbought, neutral-bullish
ATR	26.18	About 3.6% of price; 2×ATR is about 52 points
OBV	465.25M (peak 502.34M on 09-24)	Confirms the rally, no clear divergence
TD-9 weekly / monthly / daily	-6 / -2 / +4	Weekly sell setup building; daily buy setup is pullback only
Z-Score weekly / monthly / daily	+2.00 / +1.05 / +0.71	Weekly price stretched; daily near mean
Key levels	Resistance 744.10, 751.66, 777.59, 779.82. Support 721.70, 713.19, 689.77, 680.67, 665.23, ~622–627	Reference only, no bounces verified
Data discrepancies	None found	RSI, MACD and ATR matched the snapshot

Sentiment Analyst¶

Overall Sentiment: Neutral (Score: 5.0/10) Confidence: Low

Data availability: no usable sentiment data was supplied for META for 2026-09-24 to 2026-10-01. This report is a placeholder read, not a sentiment measurement.

1. Source-by-source breakdown - Yahoo Finance news: Unavailable. The placeholder says the feed only serves recent items, so this is a retrieval limit and does not mean META had no news. I have 0 headlines and can't characterize institutional framing. - StockTwits: Unavailable, for the same stated reason. I have 0 messages, so there is no Bullish/Bearish ratio, no sample size and no retail read on $META. - Reddit (r/wallstreetbets, r/stocks, r/investing): Skipped. The sentiment_include_reddit config disabled it. I have no posts from any subreddit.

2. Cross-source divergences and alignments None can be assessed. All three sources are empty, so there is nothing to compare.

3. Dominant narrative themes None can be identified from the evidence provided. I have not inferred themes such as AI capex, ad revenue, Reality Labs or regulatory issues, because nothing in this prompt supports them.

4. Catalysts and risks - No catalysts or risks surfaced from the data. I have no earnings dates, product news or macro headlines for this window. - The main risk is the data gap itself. A "Neutral" label here reflects missing information, not balanced opinion. The trader should not treat it as a signal that sentiment is calm or evenly split.

5. Summary table

Signal	Direction	Source	Supporting evidence
News framing	Unknown	Yahoo Finance	Feed unavailable; 0 headlines
Retail Bullish/Bearish ratio	Unknown	StockTwits	Feed unavailable; 0 messages
Community discussion	Unknown	Reddit	Skipped by config; 0 posts
Overall	Neutral by default (no data)	All	No evidence in any source

Recommendation for downstream use: Give this report no weight in the trade decision. Rely on fundamentals, technicals and any sentiment data re-fetched from a source that covers this window.

News Analyst¶

META news and macro report, week to 2026-10-01¶

Data coverage¶

My tools returned very little for this report, so it is thin on evidence.

Source	Status
META company news (9/24–10/1 and 9/1–10/1)	Unavailable. The feed only serves recent items. The tool said this does not mean META had no news.
FRED macro series (fed funds, CPI, 10Y, unemployment, VIX)	Unavailable. The FRED API key is not configured. I have no values for these and have not estimated any.
Prediction markets (Fed cut, recession)	Withheld for 2026-10-01. Polymarket only serves live odds, so serving them would leak later information.
Global news	Returned, but it is mostly headlines with no text, and little of it is relevant to META.

What the global headlines show¶

These come from headline titles only. I couldn't read the article text, so I can't confirm any details.

Equities, 10/1: One Yahoo Finance headline says the Dow, S&P 500 and Nasdaq "stage comeback as Treasury yields fall, chip stocks gain." That suggests a rebound from an earlier drop and falling yields on the day. I have no index levels or yield figures. Falling yields generally help long-duration growth stocks like META.
Inflation: A 10/1 silver headline mentions "the latest PCE report." The PCE data was released, but I couldn't see the figures or whether they beat or missed expectations. Check the actual print.
Risk sentiment: A MarketWatch headline quotes Jeffrey Gundlach calling the stock market "a hollow tree that could be about to snap." This is a bearish warning about narrow market breadth and concentration. It is one person's opinion, not data.
Tech and AI:
IT services and AI-adjacent stocks rallied: EPAM, DXC, Concentrix, TaskUs and IBM. IBM's move was tied to Accenture earnings.
A Barron's market-wrap headline names Micron, Accenture, Google, IBM and Synopsys.
Chip stocks gained on 10/1.
Together these suggest a supportive tone for AI and tech spending. That tone could help META's AI narrative indirectly, but the headlines don't mention META.
Commodities: Many mining and metals headlines, plus a Barchart review of September commodity performers. None bear directly on META.

Implications for META¶

I found no META-specific catalysts. The next likely catalyst is Q3 earnings, probably in late October. I'm inferring that from META's usual schedule and haven't confirmed the date.
The macro backdrop looks supportive on one day's evidence: yields fell and tech rebounded. There is also a late-cycle warning from Gundlach.
Things to check from other sources before deciding:
The actual PCE numbers and the Fed's rate path.
The 10-year yield level and the VIX.
META's price action, capex guidance, AI spending commentary, and any regulatory or legal news (FTC, EU DMA, child-safety litigation).
The confirmed Q3 earnings date.

Summary table¶

Area	Finding	Source quality	Relevance to META
META company news	None retrieved	Tool failure	Unknown, so no company-specific view
Equity markets 10/1	Rebound, with falling Treasury yields and chip strength	Headline only	Mildly positive for growth and tech
Inflation (PCE)	Report released, figures not visible	Headline only	Unknown, needs verification
Fed funds, CPI, 10Y, unemployment, VIX	No data	FRED key missing	Cannot assess the rate or macro regime
Prediction markets (Fed, recession)	Withheld	Point-in-time restriction	Cannot assess market-implied odds
Sentiment	Gundlach warns of a fragile, narrow market	Opinion headline	Downside-risk caveat for mega-cap tech
AI and tech tone	IBM, IT services and chips strong	Headlines	Indirectly supportive of the AI-spending narrative
Upcoming catalyst	Q3 earnings, likely late October	Inferred, unconfirmed	Main near-term event risk

Bottom line: I can't support a directional call on META from this data. The evidence is limited to one day of generally constructive tech and yield headlines, plus a cautionary opinion piece. The decision-maker should fill the gaps with price data, macro figures and META-specific news.

Fundamentals Analyst¶

META (Meta Platforms, Inc.) Fundamental Report, as of 2026-10-01¶

0. Data coverage and caveats¶

Profile data was withheld. get_fundamentals returned no market cap, multiples, 52-week range, or sector data for this date, because the vendor only serves present-day values. Any valuation figure below is my own rough estimate from the statements and insider-trade prices. It is not vendor data.
Latest reported quarter is Q2 FY2026 (period ended 2026-06-30). Q3 FY2026 (ending 9/30) has not been reported. Results should come in late October, which is the next major catalyst.
Q1 FY2025 is mostly blank in the income statement, so year-over-year comparisons use Q2 FY2025.
The tools do not give filing dates, and the newest insider rows may not have been public on 10/1.

1. Income statement¶

Quarter	Revenue	Op. income	Op. margin	Net income	Diluted EPS
Q2'25	$47.5B	$20.4B	43.0%	$18.3B	$7.14
Q3'25	$51.2B	$20.5B	40.1%	$2.7B	$1.05
Q4'25	$59.9B	$24.7B	41.3%	$22.8B	$8.88
Q1'26	$56.3B	$22.9B	40.6%	$26.8B	$10.44
Q2'26	$60.8B	$18.8B	30.9%	$15.8B	$6.18

Growth - Q2'26 revenue grew about 28% year over year ($47.5B to $60.8B) and about 8% from Q1'26. - Trailing-four-quarter revenue is about $228B.

Margin compression is the main issue. - Operating margin fell from 43.0% to 30.9% year over year, and about 10 points from Q1'26. - Q2 operating expenses were $30.7B, up 65% from $18.6B a year earlier. - R&D was $21.7B, up 67% year over year and up 22% from Q1. That is 35.6% of revenue. - SG&A was $9.0B, up 60% from Q1. G&A alone was $5.6B, more than double Q1's $2.6B. The data does not say why. Possible causes include legal accruals or one-offs, which should be checked in the 10-Q. - Cost of revenue was $11.3B, up 33% year over year. Gross margin slipped to 81.4% from 82.1%. - Operating income fell about 8% year over year despite 28% revenue growth.

Earnings quality is noisy because of tax items. - Q3'25 tax provision was $19.0B, which cut net income to $2.7B. Deferred tax of $19.9B in the cash flow statement points to a one-time non-cash charge. - Q1'26 had a tax benefit of $5.0B, which pushed net income to $26.8B. - Q2'26 tax was $2.9B on $18.8B pretax, a 15.5% rate. - Q2 EPS of $6.18 is down about 13% year over year and well below the prior two quarters. Q2 is the cleanest recent read on earnings power. - Other items: Q1 had a $1.3B loss on securities, and interest expense rose to $783M from $241M a year ago as debt grew.

2. Cash flow: the investment cycle is overtaking free cash flow¶

Quarter	Operating CF	Capex	Free CF	Buybacks	Dividends
Q2'25	$25.6B	$16.5B	$9.0B	$10.2B	$1.3B
Q3'25	$30.0B	$18.8B	$11.2B	$3.3B	$1.3B
Q4'25	$36.2B	$21.4B	$14.8B	$0	$1.3B
Q1'26	$32.2B	$19.0B	$13.2B	$0	$1.3B
Q2'26	$31.9B	$30.1B	$1.7B	$0	$1.35B

Capex jumped 59% from Q1 to $30.1B and was up 82% year over year. Trailing capex is about $89B against trailing operating cash flow of about $130B.
Free cash flow collapsed to $1.7B in Q2. Trailing free cash flow is about $41B, of which only about $1.7B came in the latest quarter.
Buybacks have stopped. There have been none in the last three quarters, after $10.2B in Q2'25 and $3.3B in Q3'25. Capital is going to capex and the balance sheet.
Dividends continue at about $1.35B per quarter, easily covered by operating cash flow.
Stock-based compensation was $7.7B in Q2, 12.6% of revenue and up 58% year over year. Free cash flow is overstated relative to true owner earnings.
Working capital was a small tailwind in Q2 (+$0.5B), after a $7.8B drag in Q1. Accrued expenses rose $5.9B, which flatters operating cash flow.

3. Balance sheet: leverage is rising quickly¶

Item	Q2'25	Q4'25	Q1'26	Q2'26
Cash and short-term investments	$47.1B	$81.6B	$81.2B	$90.3B
Total debt (incl. leases)	$49.6B	$83.9B	$86.8B	$112.3B
Long-term debt (ex-leases)	$28.8B	$58.7B	$58.7B	$83.7B
Net debt	$16.8B	$22.9B	$35.3B	$68.2B
Net PP&E	$162.7B	$196.8B	$218.0B	$249.7B
Construction in progress	$35.9B	$50.5B	$61.0B	$80.3B
Equity	$195.1B	$217.2B	$243.7B	$261.2B
Total assets	$294.7B	$366.0B	$395.3B	$450.0B

New debt: Long-term debt rose about $25B in Q2'26, after about $30B of issuance in Q4'25. Net debt tripled in six months, from $22.9B to $68.2B.
Liquidity is still strong. Cash and investments are $90.3B and the current ratio is about 2.2. Working capital is $69.1B.
Leverage is still moderate. Total debt to equity is about 0.43. Trailing EBITDA is roughly $112B, so net debt to EBITDA is about 0.6x.
Cash mix shifted. Cash alone fell to $15.5B, from $35.9B at year-end, as money moved into short-term investments ($74.8B).
Asset build-out: Net PP&E is up 53% in a year, and construction in progress has more than doubled. This is a sign of AI and data-center spending that has not yet entered depreciation.
Depreciation was $6.4B in Q2, up 46% year over year. It will keep rising as construction in progress is placed in service, which pressures margins.
Share count is 2.548B outstanding, up about 1.3% year over year. With no buybacks, stock compensation is diluting shareholders.
Goodwill is $23.4B, and tangible book value is $237.8B.

4. Insider activity (last 12 months)¶

Selling is persistent. There are no open-market purchases in the data.

Sept 2026 sales into the rally (prices rose from about $544 on 8/18 to about $779 on 9/24):
CEO Mark Zuckerberg sold 27,474 shares (about $21.4M) at about $775–779 on 9/24. A second 17,140-share entry the same day shows no value.
Officer Chris Cox sold 80,000 shares across 9/9, 9/15 and 9/21, about $55M at $650–725.
COO Javier Olivan sold on a near-weekly cadence (1,575 shares per week in September, plus 5,354 on 9/8). It looks like a pre-scheduled plan.
Officer Aaron Anderson sold 3,240 shares (about $2.0M) on 9/3.
August sales: The CFO, Susan Li, sold about 9,196 shares at about $550 and 2,127 shares at about $690 (about $6.5M combined). CTO Andrew Bosworth sold 7,848 shares at about $558 and Curtis Mahoney sold 1,559 shares at about $544. Several directors made small sales.
Large CFO sales in February: Li sold about 130,000 shares (about $84M) on 2/20, 2/24 and 2/27 at $630–650.
Gifts: Zuckerberg gifted 591,690 shares on 7/31/2026 and 639,347 on 10/31/2025. These are not sales.
Vesting: The many entries with no price on 2/13, 5/15, 8/14 and 11/14 look like quarterly RSU vesting or tax-withholding events, not discretionary trades.
Reading it: Most selling looks routine, with small amounts relative to holdings, scheduled sales, and compensation-driven sales by officers. The sizeable sales by Zuckerberg and Cox near the highs are worth noting but are not a clear bearish signal. There is no insider buying to counter them.

5. Valuation (my rough estimates, not vendor data)¶

The most recent insider trades show a price of about $750–780 in late September.
With 2.548B shares, market cap is roughly $1.9–2.0T.
Trailing four-quarter diluted EPS is about $26.55, which gives about 28–29x. This is distorted by the tax items (the Q3'25 charge and Q1'26 benefit roughly offset).
Trailing free cash flow of about $41B implies a yield of only about 2%, and the latest quarter's pace is far lower.
Price/book is about 7.5x.
The stock has rallied about 40% from mid-August lows, so expectations have risen into the Q3 report.

6. Takeaways for traders¶

Bullish points - Revenue growth is accelerating at about 28% year over year. - Gross margin is above 80%. - Operating cash flow is about $32B per quarter. - Liquidity is $90B and leverage is modest. - The balance sheet has room to fund AI investment.

Bearish points and risks - Operating margin fell to 30.9%, with expenses growing faster than revenue. Depreciation will increase as construction in progress is placed in service. - Free cash flow was close to zero in Q2, and the buyback has been suspended. - Net debt tripled in six months, and interest expense is rising. - Insiders are selling into strength, with no buying. - The stock has re-rated sharply after the August lows, so a Q3 miss on margins or capex guidance could cause a big move.

What to watch - Q3 results in late October, especially the capex guide for 2026 and 2027, operating margin versus the Q2 level of 31%, and any explanation of the jump in G&A. - Whether buybacks resume or more debt is issued. - Whether free cash flow recovers or capex keeps climbing. - Further Form 4 filings (Olivan, Cox, Zuckerberg).

7. Summary table¶

Category	Key data point	Implication
Revenue (Q2'26)	$60.8B, +28% year over year, +8% from Q1	Strong top-line growth
Operating margin	30.9%, down from 43.0% a year ago and 40.6% in Q1	Sharp compression from R&D and G&A
R&D	$21.7B, +67% year over year, 35.6% of revenue	Heavy AI investment
G&A	$5.6B, more than double Q1	Unexplained; check the 10-Q
Net income / EPS (Q2'26)	$15.8B / $6.18 (Q2'25: $18.3B / $7.14)	Earnings down about 13% year over year
Tax distortions	Q3'25 $19B charge; Q1'26 $5B benefit	Use Q2 as the cleaner read
Operating cash flow (Q2)	$31.9B; trailing about $130B	Core cash generation remains strong
Capex (Q2)	$30.1B, +82% year over year; trailing about $89B	Spending is accelerating
Free cash flow (Q2)	$1.7B (Q1: $13.2B); trailing about $41B	Close to zero in the latest quarter
Buybacks / dividends	$0 buybacks for 3 quarters; $1.35B dividend per quarter	Capital is going to capex
Stock-based compensation	$7.7B, 12.6% of revenue	Dilution and overstated free cash flow
Cash and investments	$90.3B	Strong liquidity
Total debt / net debt	$112.3B / $68.2B (net debt was $22.9B in December)	Rapid leverage build; still manageable
Net PP&E / construction in progress	$249.7B / $80.3B	Depreciation pressure ahead
Equity / debt-to-equity	$261.2B / about 0.43	Moderate leverage
Insider activity	Net selling (Zuckerberg, Cox, Olivan, Li, Bosworth); no buys	Mostly routine, but no insider support
Price context	About $750–780 in late September, up about 40% from mid-August	Elevated expectations into Q3
Valuation (rough)	Market cap about $1.9–2.0T; about 28x trailing EPS; free cash flow yield about 2%	Not vendor-confirmed
Next catalyst	Q3'26 earnings, late October	Watch capex guide, margins and G&A

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # The Bull Case for META: Investing Through the Build-Out

I'll open by naming what the bears will say, then explain why I think they're looking at the wrong half of the picture. The data below comes from the provided reports. Where I make a calculation, I say so.

1. The core business is accelerating at scale¶

Revenue grew about 28% year over year in Q2'26, from $47.5B to $60.8B. That is a roughly $228B trailing revenue base growing faster than most companies a tenth its size.
Gross margin is 81.4%. Demand is not weakening and pricing power is not eroding. That is the profile of a business spending from strength.
Operating cash flow was $31.9B in Q2, up about 25% from $25.6B a year ago. Trailing OCF is about $130B, roughly 7% of the current ~$1.85T market cap (my estimate: 2.548B shares × $725.93).

2. The margin compression is a choice¶

The bear will point to operating margin falling from 43.0% to 30.9%. R&D was $21.7B, 35.6% of revenue. That is deliberate AI investment, not a collapse in unit economics.

G&A looks like noise. G&A was $5.6B against $2.6B in Q1. If it had stayed at the Q1 level, operating margin would have been about 35.9% (my hypothetical, not a reported figure). The 10-Q should explain it, and one-time items like legal accruals are a plausible cause. I won't claim that as fact.
Operating income was still $18.8B in a quarter. Trailing operating income is about $87B.

3. Low free cash flow reflects timing, not weakness¶

Q2 free cash flow of $1.7B is the bear's favorite number. Look at what's behind it.

Capex was $30.1B against OCF of $31.9B, so the business nearly funds its own build-out in a quarter.
Construction in progress has more than doubled to $80.3B and net PP&E is up 53%. That capacity hasn't gone into service or started producing revenue yet. The spending comes first and the returns follow.
Trailing free cash flow is still about $41B. We are early in the build, not at the end.

4. The balance sheet can carry this¶

Net debt tripled to $68.2B, but from a very low base.

Cash and investments are $90.3B, the current ratio is about 2.2, and total debt to equity is about 0.43.
Net debt to EBITDA is about 0.6x on roughly $112B of trailing EBITDA.
Interest expense of $783M against $18.8B of quarterly operating income is covered more than 20 times.

This is not a stretched borrower. It is a company with ample capacity choosing to use some of it.

5. Valuation is reasonable for the growth¶

Valuation data was withheld, so these are my estimates.

Enterprise value is about $1.92T. That is roughly 17x trailing EBITDA and about 22x trailing operating income for a company growing revenue near 28%.
Trailing EPS of $26.55 gives about 27x, but it is distorted by the $19B Q3'25 tax charge and the $5B Q1'26 tax benefit, which roughly offset each other.

I would not call that a bargain, but it is not a bubble multiple for this growth rate.

6. The technical picture is constructive¶

SuperTrend is up on weekly, monthly and daily timeframes. Price is far above the 50 SMA (622.21) and 200 SMA (626.98), and the 50/200 golden cross is close (the 50 SMA is still about 4.8 points below).
OBV confirms the rally. It peaked on the same day as price (9/24) with no divergence.
The pullback has been quiet. 10/1 volume of 12.4M was the lowest of September, which points to a pause, not distribution.
RSI reset from 80.55 to 61 without price breaking down. That is a trend digesting gains.
The 10/1 headlines (falling yields, tech rebounding) are mildly supportive, though I only have titles.

7. Insider selling is mostly routine¶

Olivan's sales are near-weekly and the same size each week, which looks like a scheduled plan.
Zuckerberg's 9/24 sale of about $21.4M is small against a stake that, from general knowledge outside these reports, is in the hundreds of millions of shares. His much larger 7/31 gift of 591,690 shares was not a sale.
Most of the no-price entries on 2/13, 5/15, 8/14 and 11/14 look like quarterly vesting or tax withholding.

Where I'm not claiming certainty¶

Q3 earnings in late October (date unconfirmed) are the real test. The stock is up about 33% in six weeks and expectations have risen.
I don't know what caused the 9/21 gap (+11.4% on 48.7M shares). The tools didn't say. Sentiment and news feeds returned nothing, so I'm not leaning on them.
Short-term risks: the weekly z-score is +2.00, the weekly TD-9 count is at 6, and a bearish MACD cross looks near (histogram +0.80). That argues for patience on entries. A pullback toward the 10 EMA (721.70) or the Bollinger midline (689.77) is better than chasing, and the 680.67 daily SuperTrend stop gives a clear risk line.

What I'd ask the bear to address¶

If revenue is growing 28% with an 81% gross margin, why is a $30B quarterly capex pace evidence of failure and not of demand for compute?
With net debt at 0.6x EBITDA and over 20x interest coverage, what makes the leverage dangerous?
If G&A normalizes, how much of the margin story disappears?

What would change my mind is a Q3 report showing operating margin sliding below Q2's 31%, capex guidance rising without revenue acceleration, and G&A staying elevated with no one-off explanation. Until then, the primary trend, the growth rate and the balance sheet all favor owning META, with entries sized around ATR (26.18) and a pullback preferred to a chase. Bull Analyst: # Bull Rebuttal: Where You're Right, and the Number We Both Got Wrong

You made several fair hits, so I'll take those first. Then I'll correct a number that has been distorting this debate, mine included.

What I concede¶

"Accelerating" isn't demonstrated. With Q1 FY25 blank, one clean year-over-year comparison can't show acceleration. What the data supports is 28% growth on a $228B base.
I skipped 9/28. That was a 27.9M-share, -4.8% day. It was real distribution.
The golden cross hasn't happened. A 33% spike dragging the 50 SMA toward a flat 200 SMA isn't independent confirmation.
My "patient entry" is nearly here. The close of 725.93 is 0.6% above the 10 EMA.
The tax claim cuts both ways. I was wrong that the items offset. You overcorrected, though, and I'll get to that below.
Q2 EPS is flat even with the generous G&A add-back. The depreciation wave is a real cost, and I'd put it at several margin points, though phased in over several quarters, not one.

The correction: net debt is about $22B, not $68B¶

The "net debt $68.2B" in the fundamentals report, which I repeated and you built your slope argument on, appears to subtract only cash from long-term debt. It reconciles in Q2 ($83.7B − $15.5B = $68.2B) and, to rounding, in Q4'25. It ignores $74.8B of short-term investments, even though the same report counts them in the $90.3B of liquidity. On a consistent basis:

$B	Q4'25	Q1'26	Q2'26
Total debt incl. leases	83.9	86.8	112.3
Cash + short-term investments	81.6	81.2	90.3
Net debt, consistent	2.3	5.6	22.0
Net debt as reported	22.9	35.3	68.2

That is about 0.2x trailing EBITDA, and net cash if you count only the $83.7B of non-lease debt. The slope is real, up about $20B in six months, but it is less than half the $45B you cited, and it started near zero. Even if quarterly interest doubled from $783M to about $1.6B, Q2 operating income would cover it about 12x.

This also changes your borrowing story. In Q2, debt rose $25.5B and cash plus investments rose $9.1B. Free cash flow was still positive after dividends, so the borrowing wasn't plugging a shortfall. They raised capital ahead of need while holding $90B. I'll grant one open item: about $16B of the net-debt increase isn't explained by FCF and dividends. Leases don't explain it, since non-bond debt moved only about $0.5B. Acquisitions, strategic investments and RSU tax withholding are candidates, and I'd want the investing and financing lines.

Valuation: both our P/Es are off¶

You added back the full $19B charge and subtracted the full $5B benefit. But a normal quarter carries about $3.4B of tax at the 15.5% Q2 rate. Normalizing both quarters to that rate (my arithmetic):

Q3'25 excess tax was about $15.6B.
Q1'26 excess benefit was about $8.4B.
The net drag is about $7B, not $14B. Clean trailing EPS is about $29.4, so the P/E is about 25x, not 22-23x.

Your annualized-Q2 figure of about 29x is the right bearish bracket. So the stock is 25-29x earnings and about 17x trailing EBITDA, which is closer to 18-19x on Q2's run rate. That is not cheap, but it isn't a bubble multiple for 28% growth.

On the "33% in six weeks" framing, you picked a trough. The insider sales on 2/20-2/27 printed at $630-650, so the stock fell about 19% to the July low of 524 and has since recovered to about 13% above February levels. Nothing in the data explains the 9/21 gap, and I've said so. But this is a round trip, not a rise from a flat base.

Margin: the real debate¶

On incremental economics you're right: revenue +$13.3B, operating income -$1.6B. But gross profit grew about 27% (roughly $39.0B to $49.5B), and gross margin slipped only 0.7 points even though depreciation grew 46%. If the infrastructure weren't earning, I'd expect that line to show it. That is weak evidence, since I can't see how depreciation is allocated, but it points the right way. The margin erosion sits in R&D (+67%) and a sequential G&A jump that isn't explained.

I don't need margin to recover. Suppose revenue grows 20% on the trailing base (about $274B) and margin holds at Q2's 31%. Operating income is about $85B, roughly the trailing figure, at about 22x EV/EBIT. That is a scenario, not a forecast. It means the price assumes no heroic recovery, and each margin point above 31% adds about $2.7B.

The tape¶

Higher low: the 10/1 low of 721.51 is above the 9/28 low of 713.19, and OBV (465M) is above its 9/28 trough of 449M. Your "lower highs" list skips 9/28 (715.62) and 9/30 (725.18). Since 9/28 it has been a bounce and then flat.
Risk and reward: from 725.93, the 680.67 daily stop is -6.2% and the prior high is +7.1%. That is about 1:1, and you're right that it's unattractive. From the Bollinger midline near 690, a stop at 665 is -3.6% against +12.7% to the prior high, about 3.5:1. These are reference levels, not verified supports. Entry price matters more than the thesis does on this tape.

Insiders¶

There are no purchases in 12 months, but there were none at $525-545 in July and August either. The CFO, the CTO and Mahoney sold at about $544-558 in August, so the selling happened at the lows as well as the highs. That pattern fits scheduled compensation sales, not a view on price.

Where I land¶

I'm bullish on the business and disciplined on price. I'd hold existing exposure and add near 690-700 if it pulls back, with a stop on a daily close below 680.67 (the 2×ATR level is about 674). A starter position at today's level is defensible only if you want exposure going into the print, and I'd size it small.

My tripwires are narrower than before. I'd turn cautious if Q3 shows revenue growth below about 20%, operating margin below 31% without a G&A explanation, and a higher capex guide with no revenue acceleration. All three together would break my thesis. Q3 earnings are probably in late October, but the date is unconfirmed.

Two questions for you:

With net debt near $22B and 12x interest coverage even at double the interest, what is your leverage objection now?
If margin settles near 31% and revenue compounds near 20%, what multiple is fair for an 81% gross-margin franchise, and how far is that from 22x EBIT? Bull Analyst: # Bull Rebuttal: I'll Pay the $16B Bill, but the Price Case Isn't Settled

You won several points, so I'll start there.

What I concede¶

OBV isn't accumulation. A +0.1% close credited the full 12.4M shares, so I'm dropping it. The higher low (713.19, then closes of 715.62, 725.18 and 725.93) stands on its own, but it's a small one.
My 690/665 setup was inside one ATR. With a 2×ATR stop (about 638) it's roughly 1.7:1, not 3.5:1.
"Timing" was the wrong word. If the build is early, FCF stays near zero for a while. That is a choice, and it only works if the returns arrive.
I can't name what changed since August 20. On this data, 16.6x to 22x is multiple expansion, and the unexplained 9/21 gap is part of it.
You caught a real inconsistency. I held margin at 31% while granting several points of depreciation. I fix that below.

Where the $16B went: it isn't a Q2 event¶

I ran the same test on every period the data allows, on the consistent net-debt basis. All of it is my arithmetic.

Period	FCF minus dividends and buybacks	Change in net debt	Outflow not captured
Q3+Q4'25	+$20.1B	-$0.2B	~$19.9B
Q1'26	+$11.9B	+$3.3B	~$15.2B
Q2'26	+$0.35B	+$16.4B	~$16.7B
Four quarters	+$32.4B	+$19.5B	~$52B

About $13B a quarter has gone somewhere FCF, dividends and buybacks don't show, in every period I can test. That changes the picture in three ways:

It isn't one deal. A recurring outflow points away from a one-off acquisition.
The Q2 step-up in net debt is mostly the capex story. FCF fell from $13.2B to $1.7B, which I already own. The leak was about the same size in Q1.
It still hurts my FCF framing. Net debt rose $19.5B over a year in which reported FCF was $41B. I'm retiring $41B as "owner cash."

Candidate explanations:

RSU net-settlement taxes. The insider data shows one vest date per quarter, which fits a recurring outflow. A rough equity roll-forward leaves about $20B of unexplained equity reductions. It uses net income of $68.1B, dividends, buybacks, and trailing SBC of about $27B, which I estimated because only Q2's $7.7B is in the data. OCI or stock-funded deals could move that figure.
Other assets. Total assets less net PP&E less cash and investments rose about $25B in a year. That is consistent with receivables, investments and prepaids, but the data doesn't itemize it.
Separate from the leak: your $8B of non-cash PP&E additions is future cash out, and I grant it.

The net-settlement part is a real cost of SBC, but SBC is already expensed inside EBIT. So this hurts any FCF-yield argument more than an EBIT-based one. Cash withheld at vest can exceed the grant-date expense when the stock has risen.

The margin bridge¶

Your depreciation estimate of about $3.0B is roughly 5 margin points. Normalizing G&A to Q1's level adds about 5 points back, which takes margin from 30.9% to 35.9%.

G&A is a one-off: the two roughly cancel and 31% survives.
G&A isn't a one-off: margin is about 26%, EBIT on $274B of revenue is about $71B, and today's EV is about 26x.

The valuation debate comes down to one line item I can't verify, and Q3 should show it. Revenue growth also dilutes the depreciation hit over several quarters, but I won't count on that.

On the multiple, a year-two view puts your "high-teens" in context. If revenue grows 20% again to about $328B, EBIT is about $102B at 31% margin and today's EV is about 18.4x. At 26% margin it's about 21.9x. That is a scenario requiring two years of 20% growth, so it isn't comparable to a trailing multiple. It does show that your 18-19x is what the stock trades at on year-two earnings, and the real argument is whether year two is the right base.

Show me the revenue line¶

I can give you a partial answer. Annualized revenue per dollar of in-service net PP&E (net PP&E less construction in progress) was:

Q2'25: 1.50x ($190B / $126.8B)
Q2'26: 1.44x ($243B / $169.4B)

In-service assets grew 34% and the revenue run rate grew 28%. So the capital already placed in service has kept most of its productivity. The caveats cut my way less than yours. It's backward-looking, the $80.3B of construction in progress is untested, and much AI compute serves R&D rather than ads. Treat it as a ceiling on what the construction in progress could support, not a promise.

Tape and plan¶

Stops don't protect through a print. The 9/21 gap was +11.4%. Into earnings I size for a gap to about 665 (-8.4%), not for the stop.
We agree on 665. From there, a stop just under 627 (the 200 SMA, about 1.5 ATR) risks about 5.7% against +16.9% to the 777.59 high, roughly 3:1. These are reference levels, not verified supports.
Existing holders: hold a core position and make no adds above about 700.
New money: nothing at 726. At 690-700 I'd start small and size for the wider stop. The main purchase is near 665 or after Q3 explains G&A and capex.
Why not trim into the print: trimming is a forecast of a bad print. The primary trend is up on all three SuperTrend timeframes, and the weekly stop is at 563. This is a sizing disagreement, not a thesis disagreement.

Your three questions¶

Capex and FCF over the next two prints. I have no guidance, so this is an assumption: capex of $30-35B and operating cash flow of $32-36B, which gives FCF of about -$3B to +$5B. My thesis breaks if FCF is negative while revenue growth falls under 20%.
What justifies 16.6x becoming 22x. Nothing I can identify. The August 20 price came right after the Q2 margin and capex shock, which makes it a poor anchor for fair value. February's $630-650 on 41% margins is the other anchor. Today's price is above both, which is why I'm not chasing.
The $16B. Probably a mix of net-settlement taxes and investments. The first is a real cost already inside EBIT, and the second sits on the balance sheet. It hurts my FCF story and leaves the EBIT valuation intact.

Two questions back¶

If Q3 shows G&A normalizing and margin at or above 31%, would you move off 18-19x, or is that multiple anchored to the August price? What evidence would change it?
You'd get interested at 665. What would you need to see to buy at 690-700 instead of waiting? Bull Analyst: # Bull Closing: What's Left to Disagree About

You've narrowed this debate a lot, so I'll concede first and then say where I still disagree.

What I concede¶

My Q3 tripwire was mis-specified. If G&A normalizes, margin should be near 35%. A print at 31% would mean underlying margin fell about 5 points, so it can't count as a pass.
Q2 FCF was flattered by accruals. Accrued expenses rose $5.9B, and if part of the G&A jump is a reserve, that cash goes out later.
After the leak, "owner cash" is near zero. I've already retired the $41B figure.
The 11/14 vest will cost more. At about $726 against about $545-558 in August, net-settlement withholding is roughly 30% larger per share.
I can't tell whether construction in progress earns its keep. Nothing in this data shows that, and I won't pretend otherwise.

1. The leak is a real cost, but not a valuation-changing one¶

Net settlement offsets dilution. You charge me for 1.3% dilution and for the cash withheld at vest. Withholding shares in exchange for cash is how that dilution gets reduced, so it's one cost, not two.
The size is manageable. If the vest is the main leak, 30% more per quarter is a few billion dollars against $32B of quarterly operating cash flow. It's already expensed in EBIT, so it hurts FCF yield more than EBIT value.
A one-time G&A accrual doesn't move value. Even if the full $3.0B is a legal reserve paid out later, that's about $1.18 per share (my arithmetic), or 0.16% of market cap. It distorts Q2 margin and Q3 cash flow. It doesn't change what the business is worth.
FCF less the leak is not "cash burned." Your -$11B treats all $52B as consumed. Only net-settlement taxes (~$20B on my estimate) are clearly consumed. Leases (~$8B) bought assets. The remaining ~$24B may be investments or deposits, or it may be waste. We don't know, so I won't call it an asset and you shouldn't call it a loss.

2. Returns on in-service assets: the numerator matters¶

Your 0.64 to 0.44 uses operating income. Here is gross profit per dollar of in-service net PP&E, annualized (my arithmetic):

Q2'25: $156.0B / $126.8B = 1.23
Q2'26: $198.0B / $169.4B = 1.17

That is down about 5%, not 31%. Of the $13.3B of added revenue, $10.5B reached gross profit. Opex took $12.1B, and R&D alone rose about $8.7B.

I don't think this settles it. R&D likely absorbs depreciation on training infrastructure, so some of the "R&D problem" is really the asset problem. The data can't separate them. What it does show is that the decline sits in opex and not in cost of revenue, and the dollar test below is the only clean way to resolve it.

3. The Q3 test: I accept dollars, with one amendment¶

I'll adopt your framework. On your illustrative ~$65B revenue:

Outcome	Operating income	Margin	Read
Pass	≥ ~$22B	≥ ~34%	G&A explained, R&D growth slowing, FCF positive
Ambiguous	$20-22B	31-34%	Neither thesis proven
Fail	< ~$20B	< 31%	G&A not one-off or depreciation outrunning growth, and my thesis breaks

The amendment is on capex. A higher guide with accelerating revenue is a pass, because it signals demand. A higher guide with revenue growth below 20% is a fail. "Capex not rising" as a pass condition would reward a company for under-building into demand.

4. Valuation: the gap is smaller than it looks¶

On your good case (35% margin, 20% growth, ~$96B EBIT), using ~$22B net debt and 2.548B shares (my arithmetic):

Multiple	Per share	vs. $726
18.5x (your range)	~$688	-5%
20x	~$745	+3%
22x	~$820	+13%

On your own good case, the stock is within about 5% of your fair value. The remaining gap is 18.5x versus 20-22x, and that's a judgment about an 81% gross-margin franchise growing 20% or more. I'm not claiming it's cheap. If the print is good, today's price is roughly fair, and the upside comes from year-two compounding. If the print is bad, the downside is the $590-665 range we've both laid out.

5. The waiting problem¶

You'd buy "anywhere in the 690s" after a good print. But the 9/21 gap was +11.4% in one session. A print that clears your pass bar could easily gap through the 690s and never come back. Paying for confirmation costs price, in the same way that holding through the print costs you if it fails.

This is why I won't trim to zero. We now agree on the sizing rule: hold only what survives a -10% gap (about 650). Above that, we differ on whether the remaining exposure is a forecast of a bad print or a hedge against missing a good one. I treat it as the hedge.

Final position¶

Holders: keep a core position sized to survive a gap to ~650. Make no adds above ~700 before the print.
New money: nothing at 726. A small starter near 690 is defensible, with the stop sized to 2×ATR. The main add comes on a pass at Q3 or a pullback toward 665.
Thesis breaks if: Q3 operating income is under about $20B with G&A unexplained, FCF turns negative, and revenue growth falls below 20%. Rising capex with those conditions is the clearest failure.

What I haven't verified¶

I don't know why the stock gapped on 9/21, what G&A contains, where the ~$24B of the leak went, or the confirmed Q3 date. The sentiment and news feeds were empty, so I haven't relied on them.

What we agree on is the business quality, the balance sheet, the entry discipline and the sizing rule. What we disagree on is whether a rational holder pays 20x for the chance that Q3 confirms the margin recovers, or waits and risks paying more. Bull Analyst: # Bull Final Reply: Entry Price Is the Whole Argument Now

The bear's closing narrows the debate to one question: what price makes the Q3 bet worth taking? I'll concede what the numbers force, then show where I think the bear's framing overreaches.

What I concede¶

The thesis-break rule needed all three conditions at once, so it could never fire. I'm dropping it. The table is the rule: Q3 operating income under about $20B (margin under about 31%) breaks my thesis, with no other conditions needed.
The total-basis asset return fell about 17% (0.96 to 0.79 gross profit per dollar of net PP&E). It will keep falling while capex runs ahead of revenue. My capex amendment (higher capex only with accelerating revenue) is the test for it.
EPS is unanswered. Even with the full G&A add-back, Q2 EPS is about flat year over year on 28% revenue growth, and more depreciation is coming. I can't rebut that from this data, so Q3 dollars have to settle it.
About $24B of unexplained outflow is about 28% of trailing operating income. That is not trivial. The Q2 10-Q's investing and financing lines should show where it went, so we should read them before the print instead of arguing about it.
Pass at roughly fair value is the bear's point and it's correct. On our shared numbers, a good print gets you to about $688-745, not a bargain.

Where the bear's framing overreaches¶

"Any upside needs the multiple to move up again." Not over a holding period longer than one print. At a constant 20x, EBIT growing 20% a year grows the equity value about 20% a year. The 16.6x-to-22x re-rating is unexplained and I won't defend it. But the bull claim isn't multiple expansion. It is that a pass gives you a fairly priced business compounding at about 20%. Print-to-print payoffs hide that.

The waiting cost is also uncertain. The bear puts it at 3-13% if a pass re-rates to 20-22x, and I agree. That cuts against waiting, though I don't claim it outweighs the downside.

The payoff math, done properly¶

Using our shared midpoints (my arithmetic): pass about $745 (20x on $96B EBIT) and fail about $628 (midpoint of $590-665). The pass probability needed to break even at each entry:

Entry	Pass probability needed
$726	about 84%
$690	about 53%
$665	about 32%

I have no edge on G&A, so I treat the pass as roughly a coin flip. That settles it:

At $726, don't add. Breakeven needs about 84% confidence, which I don't have. The bear is right on this.
At about $690 a small starter is defensible, since it's close to breakeven and the sizing rule limits the damage.
At about $665 the odds favor the buyer. That is also the pre-gap level, though I haven't verified it as support.

This is the same entry discipline we've both argued for, and now it has a number behind it. The fail range is also not a floor. If G&A is recurring and the multiple compresses with it, the downside could exceed -19%, which is why sizing matters more than the stop.

Final position¶

Holders: keep a core position sized to survive a gap to about $650. Make no adds above about $700.
New money: nothing at $726. A small starter near $690 is the most I'd do. The real buying is near $665 or after a Q3 pass.
Q3 test (my reading of our shared table): operating income at or above about $22B with G&A explained and FCF positive is a pass, and capex can rise if revenue growth accelerates. $20-22B is ambiguous. Below $20B is a fail, and I cut exposure.
Before the print: read the Q2 10-Q's investing and financing lines for the $24B and the G&A note for the $3.0B jump. Both are already public.

Where we still differ¶

We agree on the business, the balance sheet, the sizing rule and the dollar-based test. We differ on one thing: whether the remaining exposure through the print is a bet on a bad outcome or a hedge against missing a good one. On the payoff math, that hedge isn't worth much at $726 but is reasonable near $690 and cheaper still at $665.

What neither of us has verified¶

Why the stock gapped on 9/21.
What is in the $3.0B G&A jump.
Where the roughly $24B of outflows went.
The confirmed Q3 earnings date.
Macro and sentiment, which were empty or headline-only, so I haven't relied on them.

I'm bullish on the franchise and unwilling to chase it. The bear's case for patience on price is strong, and my case for owning the business through a drawdown still stands.

Bear Researcher¶

Bear Analyst: # The Bear Case for META: A Great Business at the Wrong Price, on the Wrong Trajectory

I'll start by agreeing with a lot of what you said. Meta isn't going to default. Revenue grew 28% year over year, cash and investments are $90.3B, and trailing operating cash flow is about $130B. I'm not arguing it's a bad company. I'm arguing that the profit and cash trends the data lets us see are all moving the wrong way, and the stock has added about $460B of market cap in six weeks on no new quarterly financials. (That figure is my arithmetic: $180.53 × 2.548B shares.) Where I do arithmetic below, I say so.

1. "Accelerating" rests on one data point, and the incremental economics are negative¶

Q1 FY2025 is blank in the income statement, so the data supports exactly one clean year-over-year comparison. You can't show acceleration from that. You can show what the extra $13.3B of Q2 revenue produced:

Operating expenses rose $12.1B ($18.6B to $30.7B).
Cost of revenue rose about $2.8B.
Operating income fell $1.6B, from $20.4B to $18.8B.

Revenue grew 28% and operating income fell about 8%. Capex was about 50% of revenue, against about 35% a year ago. On this data, growth is currently destroying operating profit.

2. The G&A add-back doesn't rescue the margin¶

I'll give you the whole $3.0B G&A jump as a one-off, though you admit you can't verify that. Operating margin is then 35.9%, which is still 4.7 points below Q1 and 7 points below last year.

The EPS math is worse. Adding back $3.0B at the 15.5% Q2 tax rate is about $2.5B after tax, or roughly $0.99 per share (my arithmetic). Q2 EPS becomes about $7.17, against $7.14 a year ago. With the most generous adjustment, revenue is up 28% and EPS is up about 0.4%.

3. Free cash flow isn't a timing blip¶

You cite trailing FCF of $41B. Look at the sequence instead: $14.8B, $13.2B, then $1.7B.

Annualize Q2 (my arithmetic): capex of about $120B against operating cash flow of about $128B leaves about $7B of FCF. Dividends take about $5.4B of that. That is a 0.4% FCF yield on a $1.85T market cap, with nothing left for buybacks or debt paydown.
Q2 stock-based compensation was $7.7B, so FCF after SBC was about negative $6B.
You say the business "nearly funds its own build-out." In the same quarter total debt rose $25.5B and net debt rose $32.9B, against FCF of $1.7B and dividends of $1.35B. The data doesn't explain the gap. Net PP&E rose $31.7B against $30.1B of capex less $6.4B of depreciation, which suggests assets are being added outside cash capex, perhaps through leases. That is my inference, not a reported fact.
Buybacks have been zero for three quarters, while the share count is up 1.3% from dilution.

4. Construction in progress is a depreciation bill, not a promise¶

You say the $80.3B of construction in progress hasn't produced revenue "yet." Nothing in the data shows what the capex earns, so "returns follow" is an assumption. Net PP&E is up about $87B (+53%) in a year, while quarterly operating income is down $1.6B.

The cost side is visible. Depreciation was $6.4B on roughly $169B of non-CIP PP&E, about 3.8% per quarter. Applying that rate to $80.3B of CIP implies about $3B more per quarter, roughly 5 points of margin at Q2 revenue (rough arithmetic, and asset mix could move it either way). That is before any further capex, and none of it is in the 30.9% yet.

5. The balance sheet: solvency isn't the question, the slope is¶

I concede the 0.6x net debt/EBITDA and the 24x interest coverage. But net debt went from $22.9B to $68.2B in six months, and it nearly doubled in the last quarter alone. Interest expense tripled year over year ($241M to $783M), and since the debt was added during the quarter, Q2 probably doesn't show the full run-rate (inference). Trailing EBITDA also includes three quarters of 40% margins that Q2 no longer resembles.

A company with $130B of annual operating cash flow that has to borrow to fund its plan has told you the plan exceeds its cash generation. We don't have the capex guidance, and Q3 will supply it.

6. Valuation: you're paying more for lower-quality earnings¶

Your tax claim is wrong. The $19B Q3'25 charge and the $5B Q1'26 benefit don't "roughly offset." Net, that's about a $14B drag on trailing earnings. I'll concede that makes clean trailing P/E lower than 27x, perhaps 22–23x. But those trailing quarters carried 40% margins. Annualizing Q2's $6.18 gives $24.72, or about 29x.
On the same Q2 financials, enterprise value to trailing EBITDA went from about 13x at the August 20 close ($545.40) to about 17x today (my arithmetic). Filing dates aren't in the data, but Q3 hasn't been reported, so nothing new in the financials explains the re-rating.
The 9/21 gap added about $194B of market cap in one session, with a cause neither of us can identify. The sentiment and news feeds were empty. A 33% move nobody can explain is a reason for caution.

7. Technicals: the tape is weaker than you present it¶

The golden cross hasn't happened. The 50 SMA (622.21) is still below the 200 SMA (626.98). That near-cross is a 33% spike dragging a flat average, not an independent confirmation.
The pullback wasn't all quiet. You cite 10/1 volume of 12.4M. You skip 9/28, a 27.9M-share down day (751.66 to 715.62, -4.8%), more than twice that volume. Closes since the peak: 777.59, 751.66, 738.79, 725.93, each a lower high.
Momentum is rolling over. MACD has fallen four straight sessions with the histogram at +0.80, ADX has dropped from 64.1 to 45.6, the weekly z-score is +2.00 and the weekly TD-9 is at 6 of 9.
Your "patient entry" is already here. The 10 EMA is 721.70 and the stock closed at 725.93. You are advising a buy now while sounding patient.
The asymmetry is poor. A fill of the 9/21 gap (665.23) is -8.4%. A retest of the 200 SMA is -13.6%. A retest of the 777.59 high is +7.1%. These levels are reference points only, since I haven't verified any bounces there.

8. Insiders¶

Zuckerberg sold about $21.4M on 9/24, the highest-close day in the data, and Cox sold about $55M across 9/9, 9/15 and 9/21. The CFO sold about $84M in February. There have been zero open-market insider purchases in 12 months. The company halted its own buyback too. I agree much of this is routine, but nobody inside is buying at $726 either.

Your questions¶

Is $30B of quarterly capex failure or demand? Neither is shown. The data shows spending up 82% against revenue up 28%, with operating income down. Show me the revenue line it earns.
Is leverage dangerous? Not for solvency. It's dangerous because it signals that FCF no longer funds the plan, and because the equity is priced as though it does.
If G&A normalizes, how much of the margin story disappears? Very little. Margin is still 7 points lower than a year ago and EPS is flat, before the depreciation wave.

Your tripwires are close to my base case: operating margin below 31% (depreciation alone could do it), rising capex guidance (the trend), and elevated G&A (unexplained).

Bottom line¶

I wouldn't initiate here. The stock is up about 33% in six weeks into a print you call "the real test," with fundamentals that have deteriorated since the lows, and a downside that is larger than the upside to the prior high. If you're long, I'd protect the gains before the print. I'd revisit after Q3 gives capex guidance and explains the G&A, or after a pullback toward the 665 gap and the 627 area. Macro and sentiment data were too thin to lean on either way, so I haven't. My case rests on the financial statements, and those say the earnings power is falling while the price rises. Bear Analyst: # Bear Rebuttal: You Fixed My Net Debt, but Not the Price

You landed several hits, so I'll concede them first.

What I concede¶

Net debt is about $22B, not $68B. Your table is right. The $68.2B subtracts only cash from long-term debt and ignores $74.8B of short-term investments. My "tripled to $68B" slope argument was overstated.
Your tax normalization is better than mine. Adding back the full $19B and subtracting the full $5B was too crude. About 25x on clean trailing EPS is a fairer number than my 22-23x.
Insiders are not a signal. Sales at $544-558 in August look the same as sales at $775. I'm dropping this point.
9/28 holds as a short-term floor. Closes of 715.62, 725.18 and 725.93 are a small higher low.
"33% in six weeks" picked a trough. The stock was $630-650 in February.

Leverage: solvency is retired, the $16B isn't¶

My objection was never default risk, and at ~0.2x net debt to EBITDA it isn't one. But your own table shows net debt rose about $16B in Q2, in a quarter where FCF minus dividends was about +$0.35B. You grant that roughly $16-17B isn't explained. "Raising capital ahead of need" doesn't account for it. That money went somewhere.

If it was RSU tax withholding, it is a disguised buyback. The real cash cost of the $7.7B quarterly SBC is higher than FCF shows.
If it was acquisitions or strategic investments, it is more capital deployed with no visible return.
You also ruled out leases, which leaves about $8B of net PP&E growth beyond cash capex ($31.7B + $6.4B depreciation vs. $30.1B). My inference, not a reported fact, is that this is capex incurred but not yet paid. That would be future FCF drag.

Meanwhile the capital-return policy flipped from $10.2B of buybacks in Q2'25 to zero buybacks and +$25B of debt.

Valuation: same scenario, different price¶

I'll use your scenario, which is $274B of revenue and a 31% margin, or about $85B of EBIT.

Price	EV (my arithmetic)	EV / scenario EBIT
$545 (8/20)	~$1.41T	~16.6x
$726 (10/1)	~$1.87T	~22.1x

That assumes Q2 was public by August 20, which is Meta's usual schedule but not confirmed here. If it was, you could have run this same scenario then, and the price implied 16.6x. The financials haven't changed, so the whole move is multiple expansion.

Your scenario also contradicts your concession. You hold margin at 31% while granting that depreciation will cost "several points." If that costs four points, margin is 27% and EBIT is about $74B. That's ~25x, not 22x. To hold 31%, you need offsetting leverage from somewhere, and R&D is growing 67%.

Your question 2. EBIT multiples flatter a business whose capex is 4.7x its depreciation ($30.1B vs. $6.4B). Q2 FCF margin was 2.8%, against 19% a year ago and 23% in Q1. At the Q2 pace, annualized FCF is about $7B, or negative after SBC. Both of the following are my arithmetic. For a 20%-growth, 81%-gross-margin franchise with capital intensity like this, I'd pay a high-teens multiple. That's my judgment, not a computed figure. At 18-19x on $85B, equity is worth roughly $590-625 per share, 14-19% below the current price.

"Early in the build" vs. "FCF is timing"¶

You said "we are early in the build, not at the end" and that low FCF is timing. Those claims conflict. If the build is early, capex keeps running at or above $30B a quarter, and FCF stays near zero. The 80.3B of construction in progress is also not yet in depreciation. Your gross-margin evidence (81.4% vs. 82.1%) is a lagging read taken before that wave. It can't show the infrastructure earns, because the test hasn't started. Cost of revenue is already growing faster than revenue (+33% vs. +28%).

The tape¶

OBV isn't a recovery. It rose from 452.9M to 465.3M on 10/1 because a +$0.75 close (+0.1%) credited the full 12.4M shares. That is a mechanical artifact.
Your 3.5:1 setup is inside one ATR. Entering at 690 with a 665 stop risks about 25 points, less than a single ATR (26.18, or about 3.6% of price). Routine noise would stop you out. With your own 2×ATR sizing, the stop is about 638, so the risk is 7.6% against 12.7% upside, about 1.7:1. From 725.93 it is about 1:1, as you concede.
The round trip cuts my way. In February the stock was $630-650 with 41% operating margins and $14.8B of quarterly FCF. Today it is at $726 with 31% margins and $1.7B of FCF. Fundamentals are worse and the price is about 13% higher, with the 9/21 gap still unexplained.

Where I land¶

I wouldn't initiate at $726. If I were long, I'd trim into the print. Your plan to add near 690-700 is reasonable in principle, but only with a stop sized to the ATR and a smaller position. I'd get more interested in the 665 area, or after Q3 explains capex guidance, the G&A jump and the $16B.

Three questions for you:

If the build is early, what quarterly capex and FCF do you expect over the next two prints?
What new information since August 20 justifies 16.6x becoming 22x on the same scenario?
Where do you think the $16B went, and does the answer help or hurt your thesis? Bear Analyst: # Bear Rebuttal: The Leak Is Real, and Your Q3 Test Is Too Easy

What I concede¶

The leak is recurring, and that weakens my FCF framing. Net debt was flat in H2'25 despite about $26B of FCF. After the leak, "good" quarters were already near break-even, so my $14.8B-vs-$1.7B comparison overstated the change in cash. The swing is the same size, but the starting point was lower. My February comparison should rest on margins and EPS, not FCF.
August 20 is a poor fair-value anchor. I used it to show the multiple moved on unchanged financials. My 18-19x comes from capital intensity, not from that price.
A year-two multiple is a legitimate framework. I dispute the inputs, not the method.
Stops don't protect through a print. Your own gap-sizing argument is the strongest case for what I say below on sizing.

The $52B: it's worse than "SBC is already in EBIT"¶

On your numbers, capex ($89B), the leak ($52B) and distributions ($8.6B) total about $150B against $130B of operating cash flow. The $19.5B gap is the net debt increase. Trailing FCF of $41B less the leak is about -$11B.

Your candidate explanations don't fully cover it:

Receivables and prepaids can't be in the leak. Working-capital changes already run through operating cash flow, so they are inside FCF. Only the non-operating part of that $25B of other-asset growth (investments, deposits, acquisitions) counts.
Lease-type debt explains some. Debt other than long-term bonds rose about $7.8B over four quarters ($62.7B total debt increase less $54.9B of long-term debt, my arithmetic). That is PP&E added without cash capex. It is a capital commitment all the same.
That leaves roughly $24B after about $8B of leases and about $20B of net-settlement taxes (your estimate, which depends on an SBC figure you extrapolated). The data doesn't say where it went.
Accrued expenses may link to G&A. They rose $5.9B in Q2, the same quarter G&A jumped $3.0B. If part of the G&A jump is an accrual such as a legal reserve (my inference only), it is non-cash now and cash later. Adding it back to margin ignores the payment still ahead.
The next vest will cost more. The vest dates are 2/13, 5/15, 8/14 and 11/14. The August vest priced near $545-558. If net settlement is the main leak, the 11/14 withholding at about $726 is roughly 30% larger for the same share count.

The revenue line: returns on in-service assets fell 31%¶

Your revenue-per-asset ratio (1.50x to 1.44x) shows ad revenue holding up. It doesn't show returns. Annualized operating income per dollar of in-service net PP&E (my arithmetic):

Q2'25: $81.6B / $126.8B = 0.64
Q2'26: $75.2B / $169.4B = 0.44

That is down 31%, or about 20% even after adding back the full $3.0B of G&A. Construction in progress is also 32% of net PP&E, against 22% a year ago, so the untested share of the asset base is growing. By your own admission, much of the new compute serves R&D, not ads.

Your Q3 test is mis-specified¶

Your tripwire is "operating margin below 31%." But your own G&A hypothesis predicts about 35.9%. If Q3 revenue is about $65B (28% growth on $51.2B, illustrative), that is about $23B of operating income. A print of 31% with G&A normalized would mean underlying margin fell about 5 points in a quarter. That confirms the bear case, so it can't count as passing.

The test I'd use is dollars. Operating income at or above Q1's $22.9B, with a capex guide that isn't rising and FCF positive.

Valuation on your scenario¶

Price	EV (my arithmetic)	EV / $85B (31% margin)	EV / $71B (26% margin)
$590	~$1.53T	17.9x	21.5x
$625	~$1.61T	19.0x	22.7x
$665	~$1.72T	20.2x	24.2x
$695	~$1.79T	21.1x	25.3x
$726	~$1.87T	22.0x	26.4x

EV/EBIT flatters a company reinvesting more than 100% of EBIT. Q2 EBIT less net investment (capex minus depreciation) was $18.8B - $23.7B = about -$4.9B. That is fine if the returns arrive, but it is the part the multiple hides. Weight your two margin cases equally and you get the mid-20s at today's price.

Your questions¶

1. Would a good Q3 move me off 18-19x? Yes, and I can quantify it. If Q3 shows about 35% margin with G&A normalized, 20% growth gives about $96B of EBIT. At 18-19x that is roughly $670-705 per share. At that outcome I'd be comfortable near today's price. The disagreement is about paying for it before the evidence.

2. What would make me buy at 690-700 instead of waiting for 665? Nothing on valuation, because 690-700 is still 21x on your good case. Even 665 is not cheap at 20x. My interest there was about risk/reward on an unexplained gap, not value. The $590-625 range is the value zone. Before the print I wouldn't buy at 690-700. After a print showing about 35% margin, I'd buy anywhere in the 690s.

Plan¶

665 and the stop. Your 627 stop is 1.5 ATR, inside your own 2×ATR rule. At 2×ATR (about 613) the ratio is about 2.2:1, and that assumes the 777.59 spike high is reachable. The 9/21 gap's cause is still unknown, so I'd treat 665 as unverified.
Trimming is sizing, not a forecast. A 3.6% daily ATR, an 11.4% gap in September, and a weekly stop 22% away mean the stop can't manage the print. Position size is the only control. I'd hold only what survives a -10% gap, about 650, since your plan already sizes for a gap to 665.
New money: none at 726. Revisit after Q3.

Bottom line¶

We agree on the business, the balance sheet and the entry price. We still disagree on what the market is paying for. Cash earned after the leak is near zero, returns on in-service assets are falling, and the stock has re-rated 33% on no new financials. A good print would fix most of this, and I've said what it would look like in dollars. I wouldn't hold full size into it. Bear Analyst: # Bear Closing: Your Pass Case Gets You to Fair Value

We agree on the business, the balance sheet, the sizing rule and that the Q3 test should be in dollars. What's left is price, and your closing numbers make my case better than I made it.

What I concede¶

The $3.0B G&A accrual doesn't change intrinsic value. At about $1.18 per share it is 0.16% of market cap. It distorts Q2 margin and Q3 cash, not what the franchise is worth.
Net settlement and dilution are partly one cost. I double-charged you. After the vest increase you describe, the extra withholding is only about $1.5B a quarter (my arithmetic on your ~$20B annual estimate). That is small against $32B of quarterly operating cash flow.
Gross profit per in-service dollar holds up (1.23 to 1.17). The margin damage sits below gross profit, not in cost of revenue.
The 33% was off a trough. I've already given that up.
The leak's $24B remainder may not be waste. We don't know where it went, so I won't call it a loss.

1. Your valuation table is the bear case¶

You wrote that on my good case "the stock is within about 5% of your fair value" and "if the print is good, today's price is roughly fair." Here are the payoffs from your own numbers:

Q3 outcome	Your implied value	vs. $726
Pass (about $96B EBIT)	$688 at 18.5x, $745 at 20x, $820 at 22x	-5% to +13%
Fail	$590-665 (your range)	-19% to -8%

On a pass, the price is fair, and any upside needs the multiple to move up again. That is the same expansion we couldn't explain from 16.6x to 22x. On a fail, you lose 8-19%. Holding through the print is a bet on the multiple on one side and on the margin on the other. Nothing in the data pays you for that risk.

Your pass bar is also thin. The table sets Pass at 34% margin or better, and your valuation case uses 35%. At the threshold you're at fair value, not cheap.

2. The waiting cost is real but smaller than the holding cost¶

You're right that a pass could gap through the 690s. Waiting costs about 3% if it re-rates to 20x ($745 against $726) and up to 13% if it goes to 22x. A fail costs 8-19%. And buying at $745 after a clean print gets the same compounding as buying at $726 before it. The difference is that you've resolved the uncertainty. I'd pay up to about 20x after a pass, because a pass would show the construction in progress is earning. I wouldn't pay it before.

3. Your thesis-break rule can't trigger¶

Your table says Fail means operating income under about $20B and "my thesis breaks." Your final position says it breaks only if operating income is under $20B, FCF is negative, and revenue growth is below 20%, all together.

Negative FCF sits inside your own forecast range of -$3B to +$5B, so it isn't informative.
Growth under 20%, from 28% a quarter ago, would be a tail event.

A rule that needs all three at once almost never fires. The table is the honest version, and I'd hold you to it.

4. The asset-return picture is worse on a total basis¶

In-service assets flatter the ratio because they exclude the $80.3B of construction in progress. On total net PP&E, annualized gross profit per dollar of assets (my arithmetic) fell from 0.96 ($156.0B / $162.7B) to 0.79 ($198.0B / $249.7B), down about 17%. As construction in progress is placed in service, the in-service ratio converges toward that unless the new assets earn what the old ones did. We agree the data can't tell us whether they will.

The R&D point also cuts against you. You said R&D likely absorbs depreciation on training infrastructure, so part of the "R&D problem" is really the asset problem. If so, the spending is a recurring cost of staying competitive, not capacity waiting for revenue.

5. The unexplained outflows are not trivial¶

Roughly $24B a year is unaccounted for after leases and your net-settlement estimate. That is about 28% of trailing operating income ($86.9B). It may be investments, and it may not. EV/EBIT assumes operating income converts to owner cash, and with capex at 4.7x depreciation plus an unexplained outflow of that size, I wouldn't give full credit for it.

6. EPS still hasn't been answered¶

Even with the whole $3.0B G&A add-back, Q2 EPS is about $7.17 against $7.14 a year ago. Revenue is up 28% and per-share earnings are flat. Your closing doesn't dispute this. The growth is going into R&D, depreciation and debt-funded assets, not to owners yet.

Final position¶

Holders: hold only what survives a -10% gap (about $650). Don't add above about $700 before the print.
New money: nothing at $726. The value zone is $590-625, and $665 is a tactical level on an unexplained gap, not a value level.
After the print: a pass in dollars (operating income at or above about $22B, G&A explained, FCF positive, and capex rising only with accelerating revenue) earns a buy up to about $745. I accept your capex amendment.
Technicals: I'm not leaning on them. The weekly z-score is +2.00, the weekly TD-9 is at 6, and a bearish MACD cross is near. Those support the sizing rule but don't prove anything.

What neither of us has verified¶

Why the stock gapped on 9/21.
What is in G&A.
Where the roughly $24B went.
The confirmed Q3 date.
Macro and sentiment data, which were empty or headline-only. I haven't relied on the Gundlach quote or the 10/1 rebound.

Your final question was whether a rational holder pays 20x for the chance Q3 confirms the recovery, or waits and risks paying more. On your own table, a pass leaves you at fair value and a fail costs 8-19%. I'd rather pay a few percent more for the evidence than hold full size without it. Bear Analyst: # Bear Final Reply: Your Payoff Table Is the Bear Case

We now agree on almost everything except the pass probability and what a holder should do about it. I'll concede what's right, then cover the three places the bull's math still points toward less exposure.

What I concede¶

Compounding beats my "multiple expansion" line. At a constant multiple, 20% EBIT growth is 20% price growth. I overstated that upside needs a higher multiple. My objection is that constant multiples are rare for decelerating growers.
Waiting has a cost. A clean pass could re-rate to 20-22x and leave me paying $745-820. I've priced that in.
Reading the 10-Q is the right next step. It's the most useful action item either of us has proposed.
The $24B is not a confirmed loss. I won't call it one.

1. Your table implies holders should trim¶

You treat the pass as a coin flip, with a pass at $745 and a fail at $628. The expected value is $686.50, about 5.4% below $726 (my arithmetic). A pass pays +2.6% and a fail costs -13.5%. Your own breakeven row says holding is a negative-expectancy bet at this price. That contradicts keeping a core position, unless the core is justified by something outside the table, such as taxes or a view that the year-two multiple holds.

The "hedge against missing a good print" is also small on your midpoints. It buys +2.6%, or +13% only if the multiple reaches 22x.

2. The sizing rule is too shallow, and I proposed it¶

I agreed earlier to hold only what survives a gap to about $650. Your fail midpoint is $628, which is below $650, and your fail range runs to $590 (-18.7%). You also say the downside could exceed that. So $650 was a rule for a mild miss. I'm tightening it: size to what you can hold through about $590-600. That is my correction as much as your concession.

3. A pass is harder than a coin flip¶

The pass bar is operating income of about $22B or more, G&A explained, and FCF positive. Take an illustrative Q3 revenue of $65B (roughly the +8% sequential pace) at Q2's 81.4% gross margin. That gives about $52.9B of gross profit, and a pass needs opex of about $30.9B or less.

Q2 opex was $30.7B. Q1 was about $23.4B, backing out R&D (+22%) and SG&A (+60%). That is a $7.3B sequential rise, $4.3B of it outside the G&A jump.
Assume G&A fully normalizes, so the base is about $27.7B. If opex outside G&A grows at Q2's pace again (+$4.3B), opex is about $32.0B and operating income is about $20.9B, a 32% margin. That lands in your ambiguous band.
A pass needs both full G&A normalization and growth in other opex slowing to about +$3.2B. Depreciation rising inside cost of revenue pushes the other way.

This is illustrative, since I can't see Q3 guidance. But it shows a pass is a conjunction of conditions, not a default. My judgment is closer to a one-in-three pass probability than 50%. At 33%, the expected value is about $667. That is why I treated $665 as a tactical level and not as a bargain. Even there, I'd be buying roughly zero expected value.

4. Your 10-Q point should be a precondition¶

You say you have no edge on G&A, then say the answer is already public. Those two statements don't fit together. If the filing explains the $3.0B, the coin flip stops being a coin flip.

If the note shows a discrete item such as a legal settlement or a one-time accrual, and opex growth outside G&A is slowing, I'd move my pass odds to 50% or higher. I'd accept a starter near $690 and pay up to about $745 after a confirmed pass.
If it shows recurring costs such as headcount, compute leases, or an ongoing legal run-rate, the fail case becomes the base case. Then even $665 is not cheap.

So the order matters. Read the filing first, then size the position. Holding full size through the print on a 50% prior you could update for free is paying for a risk you can partly remove.

5. On compounding¶

A constant 20x on EBIT growing 20% a year is the bull's best argument. Two caveats. First, the $96B pass case is already next-year EBIT, so the stock at $745 prices a year of that growth. Second, with capex at 4.7x depreciation and FCF near zero, the price depends on the market continuing to capitalize that growth at 20x as it slows. Beyond the first year, that is the part nobody has tested.

Final position¶

Holders: size to survive a fall to about $590-600, not $650. No adds above $700.
New money: nothing at $726. After reading the 10-Q, a starter near $690 only if G&A looks discrete. Without that, I'd wait for a pass, then buy up to about $745.
Q3 test: operating income of $22B or more, G&A explained, other opex growth slowing, and FCF positive. Capex can rise only with accelerating revenue.
Fail: below $20B, or $20-22B with G&A unexplained. At that point I'd expect the $590-665 range, and I wouldn't try to catch it early.

What neither of us has verified¶

The cause of the 9/21 gap.
The contents of the $3.0B G&A jump.
The destination of the roughly $24B of outflows.
The confirmed Q3 date.
Macro and sentiment data. These were empty or headline-only, so I haven't leaned on the Gundlach quote or the 10/1 rebound.

We agree it's a good franchise at roughly fair value on a good print. I think the case for a full position into a binary event, at a price that already needs the good outcome, is weaker than the bull's own table shows.

Research Manager¶

Recommendation: Underweight

Rationale: By the end, the bull and bear agreed on most things. Meta is a strong franchise: revenue grew about 28% and gross margin is about 81%. The balance sheet isn't the problem. Correctly measured, net debt is about $22B, roughly 0.2x EBITDA. Both sides also agreed there should be no new money at $726. The open question was whether holders should keep full size into Q3. The bull's own numbers say no.

What the bull got right: - At a constant 20x multiple, 20% EBIT growth means about 20% value growth a year. - Waiting has a cost, because a clean print could gap the stock past $745. - Gross profit per dollar of in-service assets fell only about 5% (1.23 to 1.17), so the margin damage is in operating expenses, not cost of revenue. - The corrected net debt figure removed the bear's leverage argument.

Why the bear won: 1. The price already assumes a good print. Even on the good case (about $96B EBIT, 35% margin), fair value is about $688-745, against $726 today. A bad print points to $590-665. 2. Expected value is negative at $726. Using the bull's own coin-flip odds, a pass at $745 and a fail at $628 give about $686.50, roughly 5.4% below the price. A pass gains about 2.6% and a fail loses about 13.5%. Holding only breaks even if a pass is about 84% likely, and the bull admitted he has no edge. 3. A pass is harder than a coin flip. It needs G&A to fall back fully and other operating costs to slow from +$4.3B a quarter to about +$3.2B. If costs keep growing at the Q2 pace, operating income is about $20.9B (32% margin), which is the ambiguous band. 4. Earnings and cash are weak. Q2 EPS was flat year over year even after adding back the G&A jump. FCF was near zero after about $52B a year of cash outflows that FCF, dividends and buybacks don't show, and about $24B of that is still unexplained. Operating return on in-service assets fell about 31%. Capex is 4.7x depreciation, and $80.3B of construction in progress hasn't started depreciating yet. 5. On the same scenario, the multiple went from about 16.6x to 22x on unchanged financials. Neither side could explain the 9/21 gap.

Why not Sell: the primary trend is up on all three timeframes, the franchise is intact, the balance sheet is sound, and a pass would justify owning the stock near today's price. This is a price and sizing call, not a broken thesis.

Missing from the data: the cause of the 9/21 gap, what is in the $3.0B G&A jump, where the roughly $24B went, the confirmed Q3 date, Q3 guidance, and any usable macro or sentiment data.

Strategic Actions: 1) Trim now, before the print. Cut to about 50% of a standard allocation, selling into strength in the $720-740 area. Size so that a fall to $590-600 (about -18%) is a loss you can absorb. A stop won't protect the position through an earnings gap, so size is the only real control. If someone holds a core position for reasons outside this analysis (taxes, for example), that is for the portfolio manager to decide.

2) No new money at $726. Don't add above $700 before Q3.

3) Before the print, read the Q2 10-Q: the G&A note and the investing and financing cash-flow lines. - If the G&A jump is a one-off and other costs are slowing: allow a starter near $690, taking the position to about 65-75% of standard. - If the costs are recurring: stay at about 50% or less, and don't treat $665 as a buying level.

4) Risk lines before the print. A daily close below $680.67 (the daily SuperTrend line), or the 2xATR level near $674, means trimming to about 35-40%. Treat $665 (where the 9/21 gap would fill) as an untested tactical level, not as value.

5) Q3 scorecard (date unconfirmed, likely late October): - Pass: operating income of about $22B or more, G&A explained, non-G&A opex growth slowing, FCF positive. Capex can rise only if revenue growth accelerates. Action: rebuild to full standard weight, paying up to about $745 (about 20x). - Ambiguous: operating income of $20-22B with G&A explained. Action: hold about 50% and wait for the next quarter. - Fail: operating income below about $20B, or $20-22B with G&A unexplained. Action: cut to 25% or less, and don't try to catch the drop.

6) Real value starts at $590-625 (about 18-19x scenario EBIT). Add there only if the Q3 results don't show a fail.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan is Underweight, which maps to a Sell sized as a trim, not a full exit. At 725.93 the price already assumes a good Q3 print: the good case gives about 688-745 and the bad case about 590-665, so expected value is about 686.50, roughly 5.4% below the price. The technicals back a trim into strength. Weekly z-score is +2.00, weekly TD-9 is at 6, MACD histogram is only +0.80 with a bearish cross close, and ADX has fallen from 64 to 46. The primary trend is still up on all three SuperTrend timeframes, so this is a size reduction and not a bearish call.

Entry Price: 735.0

Stop Loss: 680.67

Position Sizing: Cut existing exposure to about 50% of a standard allocation by selling into strength in the 720-740 area. Do not add new money above 700. If a daily close falls below 680.67 (daily SuperTrend) or the 2xATR level near 674, cut further to about 35-40%. After a Q3 fail, go to 25% or less. After a clean pass, rebuild toward full weight up to about 745. Size so that a drop to 590-600 (about -18%) is a loss you can absorb, because a stop does not protect against an earnings gap. No portfolio data was provided, so apply these percentages to your own current holding.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I'll start without waiting for the others, because the cautious positions are fairly predictable, and I think both miss the point.

The trade isn't "sell because the stock looks bearish." It's a bet that the setup into Q3 is asymmetric, and the trader's own scenario ranges show it. META is at 725.93. The good case is about 688 to 745, which means that even if Q3 goes well, the range runs from about 5% below today's price to about 2.6% above it. The bad case is 590 to 665, roughly 8% to 19% down. That is a small, capped upside against a fat downside, and it is why expected value comes out near 686.50, about 5.4% below the price. That edge isn't huge, and it rests on scenario ranges and probabilities that are the trader's judgment, not hard data. But the shape of the payoff is what matters.

Now the bullish-leaning neutral argument: the primary trend is up on weekly, monthly and daily SuperTrend, ADX is 45, and price sits far above the 50 and 200 SMAs, so don't touch it. I agree the trend is intact, and that is why this is a trim and not a full exit. But ADX has dropped four straight sessions from 64, MACD momentum has rolled over from 42.9 to 36.2 with the histogram at +0.80, and the weekly z-score is +2.00 with the weekly TD-9 at 6 of 9. None of those alone is a sell signal, and I won't pretend they are. Together, after a 33% run in six weeks, they say the easy part of the move is behind us and the next catalyst is binary.

The neutral analyst will probably say to hold and let the 680.67 stop do the work. I'd push back hard. The stock gapped 11.4% on September 21, from 665.23 to 741.25, without stopping anywhere in between. Gaps work in both directions. A stop at 680.67 does nothing if earnings open at 600. Only position size protects against that, and sizing is the whole point of this plan.

The conservative analyst will probably argue the fundamentals justify a full exit. They have real material. Operating margin fell to 30.9% from 43% a year ago, R&D is up 67%, G&A more than doubled with no explanation, free cash flow was only $1.7B in Q2, buybacks have stopped for three quarters, net debt tripled in six months to $68.2B, and insiders including Zuckerberg and Cox sold into the rally with no buying. I'll grant all of that, and it is why I'm comfortable cutting to about 50%. But going to zero ignores that revenue grew 28%, operating cash flow is about $32B a quarter, liquidity is $90B, and net debt to EBITDA is only about 0.6x. The insider selling is mostly scheduled or compensation-driven, so I wouldn't read it as a warning. A full exit would be a bearish call on a stock whose trend is up everywhere, and a clean Q3 would leave you chasing it higher.

The aggressive part of this plan is what happens after the sale. We sell into strength at 720 to 740 and hold half the position, so we still participate if the stock grinds toward 745. If the print fails, we cut to 25% or less and hold dry capital with the stock in the 590 to 665 zone, near the 200 SMA at about 627 and the lower Bollinger band at 587. If the print is clean, we rebuild toward full weight, even up to 745. That is buying strength on purpose. The cautious analysts are either frozen at full size or fully out, and either way they've picked one outcome. This plan keeps exposure to both.

A few honest limits. The sentiment report has no data, the news feed was empty, and the macro data is missing, so I'm giving none of that any weight. The valuation figures in the fundamentals report are rough estimates, not vendor data. We don't know the cause of the September 21 gap. The Q3 date is likely late October but unconfirmed. All of that is a reason to size down, not to size up.

So I'd stand by the trim. Sell about half into 720 to 740, add nothing above 700, cut to 35 to 40% on a daily close below 680.67, go to 25% or lower on a Q3 fail, and rebuild on a clean pass. Do it in proportion to your own holding, since we don't know the portfolio.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Let me start by giving ground, because you've both found real problems and I'd rather fix them than defend them.

Neutral, you're right that cutting to 25% after a failed print is selling the gap, and I'm dropping that as an automatic rule. Decide based on why it failed. If it's structural, like capex guidance or a margin outlook that keeps sliding, trim on the first bounce. If it's a one-off, hold. Conservative, you're right that "rebuild up to 745" was sloppy wording. But the contradiction isn't as deep as you made it. The 688-745 range is a pre-print view, and a clean print changes the distribution, so a rebuild after the print is paying for information, not buying a stale ceiling. I'll also take the execution points. The stock hit 735.88 intraday on October 1, so waiting for 735 was too cute. Sell the first tranche now, work the rest up into the 735-745 area, and set a hard deadline before earnings, once someone confirms the date. The 680.67 level is a review trigger, not protection. I like Neutral's version, where a close below it plus a negative MACD histogram is what shaves the position. And requiring buybacks to resume is too strict while capex is climbing.

The disagreement that remains is whether to carry 25-35%, 40%, or 50% into the print. Conservative, your argument defeats itself. You say the 5.4% edge is soft because it rests on the trader's own ranges. If it's soft, that undermines the sale, not just the half we keep. If the ranges are too low, as Neutral points out with the 777.59 close from a week ago, then the shares we keep are what pays us for that error. The less you trust the model, the closer to 50% you should stay, not the nearer to 25%. Selling 65-75% of a position is a high-confidence bet that the model is right, and you've told me you don't have that confidence.

The numbers also show the sizing gap is small. A drop to 595 costs about 9% of a standard allocation at 50%, 7% at 40%, and 4.5% at 25%. A 10% upside gap, like the 665 to 741 move on September 21, is worth 5%, 4%, and 2.5%. So moving from 50% to 40% saves under two points in the worst case and gives up about one point in the good case. Neither of those is a rounding error, but neither is a reason to rewrite the plan. At 25%, the cost of being wrong on the upside is roughly half of what the 50% position would have earned.

On the trend, Conservative, you say it's only six weeks old and the 50-day is still under the 200-day. But the 50 under the 200 is what a fast move looks like in lagging averages, as Neutral said. What matters is that all three SuperTrends are up, ADX is 45, OBV peaked with price, and the pullback came on the lowest volume of September. That doesn't look like distribution. It's also why this is a trim and not a bearish call. We don't know what caused the gap, and that ignorance applies to the downside and to a second gap up equally. The trader's own ranges put roughly two-thirds on the good case, and I wouldn't cut a position by three-quarters going into an event I think favors the upside more often than not.

The fundamentals are where your case is strongest, and I won't wave them away. Revenue up $13.3B with operating income down $1.6B is a negative incremental margin. Free cash flow of $1.7B against $7.7B of stock comp is a real concern, and 0.6x net debt to EBITDA is flattered by the capex. But Neutral's point stands: G&A going from $2.6B to $5.6B is about five points of the ten-point margin drop. If that's a one-off, underlying margin is in the mid-30s, and the whole bear case on margin looks different. We can't know that until the print, and that is exactly why you size in the middle instead of at the edge.

I'll pass on the options hedge. I have no pricing, event premium right after an 11% gap is likely expensive, and a hedged half is just a smaller position plus a cost. Selling the shares is cleaner. I'm also giving the sentiment, news, and macro reports zero weight, since they're empty. The Gundlach comment is one person's opinion.

So my position is to sell the first tranche now, finish the trim toward 735-745 by a fixed deadline, and go into the print around 45-50% of a standard allocation, applied to whatever you actually hold. I'd accept Neutral's 40% before I'd accept 25-35%. After the print, rebuild in steps based on the criteria we've already agreed on, and decide on a failed print by its cause, not at the open.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Conservative, let me take your best points first, because a couple of them land.

You're right that variance reduction doesn't need the model. Selling 55-60% of a position isn't a high-confidence bet that the model is right. It's just less exposure to an event neither of us can read, and I retract that framing. You're also right that the 627 area is an assumption, not a floor, and I never needed it to be one. And you're right that low volume on October 1 cuts both ways, so I'm dropping it as evidence. It's one data point either way.

The retained shares are where I'll be straight with you and Neutral. On the trader's own ranges, the half we keep has negative expected value, and I'm not going to pretend otherwise. What I'm doing by holding it is betting that the good-case ceiling of 745 is too low. The stock closed at 777.59 a week ago and 744.10 two days before that. A range that tops out below where the stock traded last week is partly an input, not a finding. If the ceiling is wrong, the shares we keep pay for that error, and selling most of them means betting we're right to a degree we haven't earned. That's the actual argument, not the two-thirds probability.

On the 545 tail, I'll grant that a full retrace costs 12.5% of an allocation at 50% and 10% at 40%. But that requires one print to erase the entire rally on a company growing revenue 28% with $90B of liquidity. Neutral's point stands: if you size to the retrace, you also have to size to the re-spike, and a return to 777 is 7% above today. The tail on the downside is fatter, so I accept going smaller than 50%. I just don't accept that it justifies 25%.

Your rebuild plan has the flaw you keep finding in mine. You hold 25-30%, the stock gaps to 780, and you rebuild toward 40-50% somewhere near 800. That's the buy-high pattern, and your end state is just where I'm sitting before the print. You'd have sold at 726 and bought back higher. My 745 rebuild line was sloppy, but the principle is that the 688-745 range is a pre-print distribution. After the print it's dead, and buying after it is paying for information. Your plan pays the same price with fewer shares.

I also agree with Neutral that your FCF requirement of $9-13B is close to unreachable while capex runs at $30B a quarter. That's not a rebuild rule, it's an exit with a hope attached. Use the tightened version: margin and capex guidance both have to pass, revenue growth stays in the 20s, and no FCF rebound is required, since capex is a choice. I'll grant that an explained G&A line only gets underlying margin to about 36%, below last year's 43%. But the market prices against expectations, not last year's margin, and none of us has the consensus number. That's an argument for rebuilding in steps.

On fail handling, you say diagnosing a miss in real time is hard. Capex and expense guidance come in the release and on the call, not the 10-Q, so a structural miss shows up that evening. If it's structural, trim to 25-30% on the first bounce. If it's a one-off, hold.

On the trend, you're right that ADX going from 7 to 64 in three weeks is one gap and one week, and that SuperTrend says nothing about a doubled G&A line or a capex guide. I only use it to say the trend hasn't broken, which is why this is a trim and not a short.

The sizing gap is now small. By Neutral's math the expected-value difference between 25% and 50% is about a point of allocation, and the whole argument is about the tail you're most afraid of. So I'll move toward Neutral: go in at about 40-45% of a standard allocation, 35% if the position is already large relative to the portfolio. I won't go below that, because information is thin but not negative. Empty sentiment and news feeds are tool failures, not risk signals.

On execution, I'll take the amendments. Sell about two-thirds of the trim now, work the rest on any strength through roughly 740, and finish by a hard date a week before the confirmed earnings date. If it isn't confirmed, assume late October and finish around October 16-20. A daily close below 680.67 is a review point, and only a negative MACD histogram alongside it shaves the position to 30-35%.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Conservative, you've moved the debate a long way, so I'll say what I'm taking and what I'm not.

I'll take the point that a MACD histogram at +0.80 is nearly negative already, so it's no second test. Neutral's replacement is better: two consecutive closes below 680.67, or one close below 665, the pre-gap close. That means the gap is being erased, not just noise. I also take your point that a structural miss shows up in the release and on the call that evening, and Neutral's request to write down what counts as structural and what counts as one-off before the print.

I don't take the list of unknowns. Go through it. Three quarters without buybacks is a fact, not an unknown. So is the $25B of new debt. The rough valuation figures are a note on our own paperwork, not a risk in the stock. The PCE headline came out the same day yields fell and tech rallied, so the market took it fine. The unconfirmed date is why we use a calendar deadline. That leaves two real unknowns: why the stock gapped, which cuts both ways, and whether G&A recurs. You also said you wouldn't count the empty sentiment and news feeds as risk, then used thin information as a reason to size below standard. That counts it as risk.

You dismissed SuperTrend, ADX and OBV because they only describe pre-print behavior, then used the failed test of 777 as evidence about the upside. That's also pre-print behavior, so it either counts or it doesn't. It also looks more like digestion than rejection. After the 27.9M-share down day the stock held 713 and was back at 738.79 the next session.

On sizing, I'd rather use your numbers. Down to 595 is about 18%, and a full retrace to 545 is about 25%. At 40% those cost 7.2 and 10 points of allocation. At 35% they cost 6.3 and 8.7, and at 30% they cost 5.4 and 7.5. So your 30-35% and my 40% differ by roughly one to two and a half points even in the tail you're most afraid of. Meanwhile a repeat 10% gap up is worth 4 points at 40% and 3 at 30%. Calling the extra upside "opportunity cost, not loss of capital" doesn't help, because a portfolio can't tell the difference. And your rebuild plan, 30% going in and about 50% after a pass, pays up for the shares you sold at 726. I'll concede the downside is a bit fatter, which is why I'm at 40% and not 50%.

On unknown holdings, I'll meet you partway. A standard allocation is the holder's own definition of normal, so not knowing the book isn't extra risk. It is the reason we give percentages. I'll take Neutral's default: 40% if the position is comfortably sized, 35% if it has grown into a core holding. Neutral's tax point is a good one. If it's a taxable account with a big embedded gain, trimming has a real cost, and I'd lean toward 45%.

On execution, I'll take Neutral's time-based version. Sell about two-thirds of the trim now. Leave a limit on the rest around 735-740, and if it doesn't fill, sell around October 16, or earlier if the date gets confirmed. That addresses your worry about forcing a sale into weakness. The zone is only 1.3-2% above the price, against a 3.6% daily ATR. The stock closed at 738.79 on September 29, and the October 1 high was 735.88. The deadline handles the case where the bounce never comes.

For the rebuild, margin and capex guidance both have to pass, and revenue growth has to stay in the 20s. Then rebuild about half the gap within days, to roughly 50%. Add toward 60% after the 10-Q and the depreciation path, or on a pullback toward the 10-day, not at the top of a gap.

The core case hasn't changed. At 725.93 the price already assumes a good print, and the trader's own ranges make the next few weeks a trim. But we keep 35-40% because the 745 ceiling sits below where the stock closed last week, and the trend hasn't broken. I'm giving zero weight to the empty sentiment, news and macro reports, and the Q3 date is unconfirmed. All percentages apply to whatever you actually hold.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral, I'll start with your correction because it's fair. I can't cite the 745 ceiling to justify selling and the 777 close to justify keeping 40%. The honest version is that I'm hedging model error, not claiming the model is wrong, and that is worth 35-40%, not 45-50%. You're also right that the PCE point was an inference from a headline, and I'll drop it. I'll accept your cap on the tax lean as well. A big embedded gain is a reason to land at 40%, not to carry more than that.

Conservative, you've moved a long way and I'll meet you on the default. Take 35% as the starting point, 30% if the position has grown into a core holding, and 40% if it's small or the tax cost is real. That leaves us about five points apart, so I'll go through where your remaining arguments still don't hold.

You say the unexplained gap is most of the gain we're deciding how much to keep. The numbers say otherwise. META went from 545.40 to 725.93, about 180 points. Roughly 120 of those came before the gap, from 545 to the 665.23 pre-gap close. Net of the pullback since, the stock is only about 9% above that close. So about two-thirds of the move happened on ordinary days. If the gap fully reverses, you land at 665, inside the top of the trader's bad-case range. That's about an 8% drop, or roughly 3 points of allocation at 40%. The unknown is real, but it's bounded.

Your breakeven test also works against you at this size. Going from 35% to 40% costs 0.9 points of allocation at 595 and gains 0.5 on a 10% gap up. That means the extra five points pay off if the upside is about 1.8 times as likely as the downside. Neutral showed that under a symmetric distribution the upside is two to three times more likely, with the trader's negative drift pulling the other way. That's a wash, and a wash doesn't justify the lower number. The recovery arithmetic doesn't help either. We're talking about a difference of a point or so of the portfolio, which isn't a hole anyone needs to climb out of.

On the ambiguous print, I'm with Neutral and against your pre-commitment. Defaulting ambiguity to the structural branch means you sell on the first bounce after a gap without knowing why. That's the sell-low pattern we all rejected, and it makes the plan a ratchet. Ambiguity only ever cuts the position, and only a clean pass rebuilds it. A plan built that way trends toward underexposure regardless of the facts. The market also handles ambiguity for you. If the print is murky and the stock closes under 665, the price trigger already cuts toward 30%. If it holds, you had no reason to sell.

I agree that "multiple expanded on information we can't see" cuts both ways, as Neutral said, so I won't spend more time on it. I do agree with you on tax lots. It's a bounded cost, and picking lots carefully is the right way to manage it.

The plan is a sale. Going from a full standard allocation to about 35-40% means selling roughly 60% of the position into strength at 726, based on the trader's own scenario ranges. That isn't timid. What I won't do is go to 25-30%, which would be a bearish call on a stock whose primary trend is intact on all three SuperTrend timeframes. The residual is there because the ceiling is partly an input, and the rebuild rule exists because after a clean print the old range is dead and you pay for information in steps.

So I'm taking Neutral's plan nearly line for line. Sell about two-thirds of the trim at the next open, but check the live price first, since this data ends at the October 1 close. Leave a limit at 735-740 for the rest and sell at market around October 16, earlier if the date is confirmed. Cut toward 30% on two closes below 680.67 or one below 665. Rebuild to about 50% on a clean pass, meaning margin and capex guidance both pass and revenue growth stays in the 20s. Go toward 60% after the 10-Q and the depreciation path, or on a pullback toward the 10-day average. On an ambiguous print, hold and don't rebuild. Sentiment, news and macro get no weight, and everything applies as a percentage of whatever you actually hold.

FINAL TRANSACTION PROPOSAL: SELL

Conservative Analyst¶

Conservative Analyst: I'll start with where I agree with you, because it narrows the disagreement. This should be a trim and not a full exit. Revenue is up 28%, liquidity is $90B, and most of the insider selling looks scheduled. I won't lean on Zuckerberg and Cox selling near the highs, since nothing suggests it's more than routine. The question is how much risk we carry through the print, and I think your plan carries too much and has a couple of holes.

First, the expected value argument. You say yourself that the 5.4% edge rests on the trader's own ranges and probabilities. With ATR at 3.6% a day, that edge is about a day and a half of normal movement, so I wouldn't build the case on it. And if the edge is that soft, the retained half deserves more scrutiny. Half a position in the trader's own ranges has about 1.3% of upside to 745 and roughly 4% to 9% of downside to the 590-665 zone. That is the asymmetry in your own numbers, and it argues for carrying less into the print, not defending half.

Second, your plan contradicts itself on the upside. You say a clean Q3 would leave us chasing the stock higher, and the plan rebuilds toward full weight "even up to 745." But 745 is the top of the trader's good-case range, only 2.6% above today's price. Rebuilding at the top of your own range means buying with no expected upside. Either the range is too low, in which case the EV edge disappears, or the rebuild buys the high. You can't have both.

Third, the cut to 25% on a Q3 fail happens after the gap. You made the point yourself that a stop does nothing if earnings open at 600. The same is true of that cut: by the time we know the print failed, the stock has already opened lower and the 50% position has taken the hit. The only real protection is the size we hold going in. And the daily stop at 680.67 is under 2 ATR away, so it's an ordinary-volatility level and not protection against an event.

Fourth, the trend argument is younger than it looks. SuperTrend is up everywhere, but in mid-August the stock was at 545, well below where the 200-day sits now, and the 50-day is still under the 200-day. Everything bullish in the technicals comes from a six-week move, including an 11.4% gap that nobody can explain. We have no news, no sentiment, no macro data. I'm not saying the move is fake. I'm saying we can't tell whether it's durable, and that's an argument for humility, not for holding half.

Fifth, the fundamentals are weaker than your framing. Net debt to EBITDA of 0.6x flatters, because EBITDA ignores the capex that is eating the cash. Revenue grew $13.3B year over year while operating income fell $1.6B, so growth is currently being bought at a negative incremental margin. Free cash flow was $1.7B against $7.7B of stock comp, so after SBC the quarter was negative. The company raised about $25B of debt in a quarter when buybacks were zero and FCF was near nothing. If capex keeps climbing, the next question is whether FCF turns negative. The G&A doubling is also unexplained, and that could be a one-off or a legal accrual.

Last, the execution. The plan sells into strength at 720 to 740 with an entry of 735, but price is 725.93, the MACD cross is close, ADX is falling and volume is thin. If the bounce never comes, we either hold full size into the print or chase the stock down. A conservative version scales out now instead of waiting.

So here is my adjusted version. Sell the first tranche now rather than waiting for 735, and finish the trim on any strength through 740 with a deadline well before earnings. Aim for something closer to 25-35% of a standard allocation going into the print. If you want to keep half, hedge it with defined-risk options and don't rely on a stop. Don't commit to rebuilding in advance. Define what a clean pass means first: capex guide, operating margin against the 31% in Q2, an explanation for G&A, and whether buybacks resume. Then rebuild in steps after the gap, not before it. Apply all of this as percentages of your own holding, since we don't know the portfolio, and the Q3 date is still unconfirmed.

I support the sell, but with a smaller residual position and no automatic rebuild.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Let me start with where you've moved me, because it narrows things. Selling the first tranche now instead of waiting for 735 is right. We all agree the post-gap cut is a trap. Requiring buybacks to resume is too strict. And I'll drop my options hedge, since without pricing I can't tell you the premium isn't a tax on the very event we're worried about. Selling shares is cleaner. What's left is whether to carry 25-30% or 40-50% into the print, and I still think the higher numbers rest on a weaker argument than they look.

Aggressive, take your line that selling 65-75% is a high-confidence bet the model is right. It isn't. The model's confidence determines the sign of the expected return on what we keep, but the variance reduction doesn't need the model at all. ATR is 3.6% a day, the stock has already shown it can gap 11.4% without stopping, and we have no news, no sentiment, no macro, and no explanation for that gap. We don't need a view on direction to know that less size means less exposure to an event we can't read.

You also say the shares we keep pay us if the ranges are too low. Look at what the ranges say about those shares. The good case runs 688 to 745, with a midpoint around 716, which is about 1.3% below today's price. The bad case midpoint is around 627, about 14% below. At two-thirds and one-third, you get the 686 expected value. So the retained shares lose money on average in both scenarios, and the only way they make money is if the model is wrong. Neutral said as much, and you didn't answer it. "The stock is up more often than not" is true in your own numbers, but the good case itself doesn't pay you for holding.

On your cost table, I'd flip the reading. Yes, a drop to 595 costs 9% at 50% and 4.5% at 25%, so the difference is about 4.5 points. But 595 isn't the worst case. The stock was at 545 six weeks ago and 665 before the gap. A full retrace of the gap and the rally puts it near 545, roughly 25% below here. That costs 12.5% at 50%, 10% at 40%, and about 6% at 25%. The trader's bad case floors at 590, so the tail is fatter than the ranges suggest. Upside forgone is just a smaller gain. A drawdown that big takes a rally of about a third to recover.

Neutral, you say a third-to-half sigma edge is modest and calls for a modest trade, and I agree. But a modest edge is a reason to hold a modest amount of the position we're doubtful about, and 40% is not modest for a stock with a 30-point daily range going into a binary print. Also, your humility argument, that we don't know the gap's cause so we shouldn't have high conviction either way, points at smaller size in both directions. A standard allocation was set under normal information. We're missing news, sentiment and macro, and the Q3 date is unconfirmed. When information is that thin, you hold less than standard, not roughly half.

On technicals, I'd be careful. ADX was between 6.8 and 7.4 in early September and peaked at 64 on September 25. That's not a mature trend. It's the footprint of one gap and one week. SuperTrend, ADX and OBV tell us how the stock behaved before the print, and they were bullish before every gap, up or down. They have nothing to say about a G&A line that doubled or a capex guide. Low volume on October 1 also cuts two ways. It can be a quiet pullback, or thin liquidity right before an event. The tech report itself says it didn't verify any historical bounces at the 627 area, so treating the 200 SMA as a floor is an assumption.

On your clean-pass definition, I like the idea but not the thresholds. You say a clean pass is margin back in the mid-30s or G&A explained. Even if the G&A jump is a one-off, taking out the roughly five points still leaves margin near 36%, compared to 40.6% last quarter and 43% a year ago. R&D grew 22% sequentially and depreciation will rise as $80B of construction in progress comes online. So the bar for rebuilding is a margin well below last year's, after a 33% rally. The "or" is too loose, and "capex not materially above expectations" depends on a consensus number none of us has. I'd want margin and capex guidance together, plus free cash flow moving back toward the $9-13B range of the prior quarters, not $1.7B against $7.7B of stock comp. Rebuilding to 60-70% within days of a gap up also means chasing. If a clean print takes the stock to 780, you'd be buying above your own good-case range, which is the contradiction I raised before.

On fail handling, deciding by cause is fine in principle. But "if it's a one-off, hold" requires diagnosing a margin or capex miss in real time, before the 10-Q. And "trim on the first bounce" assumes a bounce arrives. At 25-30% going in, a failed print doesn't force a decision. At 40-50% you're already down 7-9% on the position and still have to choose.

On execution, I'd push back on waiting for 744 to 752. The stock hasn't closed above 744 since September 25, ADX is falling, and the MACD histogram is +0.80 with a bearish cross close. A deadline "whatever the price" will force the second tranche into weakness. Sell most of the trim now, and finish by a calendar date in mid-October if the earnings date isn't confirmed, assuming the earliest plausible report.

So my position is the same, with the execution refined. Sell the bulk of the reduction now and the rest by a fixed mid-October deadline. Go in at 25-30% of a standard allocation, in proportion to whatever you actually hold. After the print, rebuild in steps toward 40-50% once margin and capex guidance both pass, and don't go to full weight until the capex and depreciation path is clearer. If the stock gaps up and we only own 25-30%, we've given up some gain, but we haven't lost capital.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: I think we're closer than the tone suggests, so I'll concede what's right and then say where I still disagree.

Neutral is right that ATR is 26, not 30, and that it ran 20 to 21 before the gap, so I overstated the volatility. I also accept that my free cash flow bar of $9-13B was a bad rebuild rule while capex runs at $30B a quarter. Margin and capex guidance both passing, with revenue growth still in the 20s, is the better test. Neutral is also right that empty sentiment and news feeds are tool failures, not bearish evidence. I won't count them as risk, but I also won't count them as comfort. And Aggressive is right that capex and expense guidance arrive with the release, so a structural miss shows up that evening.

Where I still disagree is with the idea that the real unknown is narrow. Neutral says it's mostly whether G&A recurs, but several other things are unresolved: - We don't know why the stock gapped 11.4% on September 21. - We haven't seen the PCE figures. - The capex and depreciation path is open, with $80B of construction in progress yet to be placed in service. - Buybacks have been off for three quarters. - The balance sheet absorbed about $25B of new debt in one quarter. - The Q3 date is unconfirmed. - The valuation numbers in the fundamentals report are the analyst's own rough estimates.

None of that is a bearish signal, but it is a reason to hold less than a standard allocation going into a binary event.

On the re-spike argument, which both of you leaned on, I don't think the two tails are symmetric. A return to 777 is about 7% above today, and a full retrace to 545 is about 25% below. At 40%, that's roughly +2.8% of an allocation against -10%. More importantly, the stock has already visited 777. It closed there on September 24, then fell 3.3% and 4.8% over the next two sessions, including a 27.9M-share down day. The market has tested that ceiling and rejected it once, so I wouldn't treat it as an unpriced upside.

Neutral's expected value math actually supports me. If the difference between 25% and 40% is about 0.8 points of allocation, that's a wash within the model's own error. But the tail difference is real. A drop to 595 costs about 7% at 40% against 4.5% at 25%, and the 545 retrace costs 10% against about 6%. When the expected value gap is under a point and the tail gap is three to four points, you take the smaller tail.

The rebuild criticism is fair, and I'll answer it directly. If I hold 30% and the stock gaps to 780, I rebuild higher than I sold. That's the cost of the insurance, and it's an opportunity cost, not a loss of capital. Aggressive says my plan pays the same price with fewer shares, and that's the point. The shares we sell are the ones we don't need to be right about. Selling at 726 and buying back at 780 is about a 7% regret on the sold portion. Being wrong the other way costs 10 to 25%.

On the stop review, pairing a close below 680.67 with a negative MACD histogram isn't much of a filter. The histogram is +0.80 and the MACD line has fallen four sessions in a row, so it will likely turn negative soon without any help. That condition is close to being met already, so I wouldn't treat it as a second, independent test.

We don't know the caller's holdings, so the default should account for that. I'd move up from 25-30% to 30-35% of a standard allocation going into the print, and allow 40% only if the position is clearly small relative to the portfolio. Neutral has that rule reversed. If we can't verify the size, we should assume the one that needs more protection.

On execution, I'll take the two-thirds now. For the remainder, I'd aim for the early end of Aggressive's window, finishing around October 16, since the earnings date is unconfirmed and a report could come sooner than we expect. After the print, rebuild in steps once margin and capex guidance both pass, to about 50%, and don't go to full weight until the depreciation path is clearer. If the miss is structural, trim on the first bounce, though at 30-35% that decision is far less forced than at 45%.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Neutral, I'll take your correction first. We do lean the same way on the size rule, and your move to 35-40% narrows the gap to almost nothing. I'll meet you there: 35% is my default, 30% if the position has grown into a core holding, and 40% only if it's small or the tax cost is real. That leaves us about five points apart, so I'll spend the rest of my time on the arguments that don't hold up.

Aggressive, you caught me on two points and I'll concede both. Three quarters without buybacks and $25B of new debt are facts, not unknowns. What's unknown is what they mean for the capex path, which the print resolves, but I accept the distinction. I'll also stop leaning on the rejection at 777. It's pre-print price behavior like everything else on the technical page, and the hold at 713 followed by the bounce to 738.79 reads fine as digestion. I'd add one small thing: 777.59 to 715.62 is an 8% drop in two sessions, and nothing around it explains why.

I do reject the idea that I'm treating empty feeds as risk. I'm not. The concrete unknown is that nobody can say why META gapped 11.4% on September 21, and that gap is most of the gain we're deciding how much to keep. That's a hole in our knowledge of the stock, not a tool failure.

Your sizing arithmetic is right, and I'll use it. Going from 40% to 30% saves 1.8 points of allocation if the stock hits 595 and 2.5 points at 545. It costs 1 point if the stock gaps up another 10%. So holding the extra ten points only pays if a 10% gap up is about twice as likely as an 18% drop. The trader's own ranges don't support that, since the good case tops out at 745. Your line that opportunity cost and lost capital look the same to a portfolio is true in dollars. But a drawdown still needs a bigger gain to recover than the gain you forgot to take.

Neutral, you said erasing six weeks of gains in one print is low probability, and I agree. But your own numbers weaken the point. If a one-sigma move over three to four weeks is 12-15%, then 595 is a 1.2 to 1.5 sigma outcome, not an exotic one. That also means a 10% gap up is about as rare as an 18% gap down, and the second costs more. Pairing 777 against the trader's 590 floor gives +7% against -18%, which is better than 2.5 to 1 against us.

Your point that Q2 was already public when the stock was near 540 is fair. But it cuts against you. If the market saw 31% margins, $1.7B of free cash flow and the debt build at 540 and then paid 726, the multiple expanded on information we can't see. The same fundamentals now have to clear a much higher bar.

I'm fine with your structural versus one-off definitions, with one addition. The middle case isn't covered. Capex up with margin flat, or G&A unexplained on the call, are both plausible outcomes. I'd pre-commit that an ambiguous print defaults to the structural branch, so nobody holds through ambiguity on a hopeful reading. Also, "underlying margin back in the mid-30s" is still well below 43% a year ago, so it's a pass only against reduced expectations.

On tax, I agree it's a legitimate cost. But it's a known, bounded cost, and you can lower it by choosing which lots to sell. It argues for choosing lots carefully, not for carrying more event risk.

On execution and triggers, I'm with you both. Sell about two-thirds now, leave a limit at 735-740 for the rest, and sell at market around October 16 or earlier if the date is confirmed. For the remaining shares, I'll take two consecutive closes below 680.67, or one close below 665, as the signal to cut toward 30%.

On the rebuild, I accept the stepped version: margin and capex guidance both pass and revenue growth stays in the 20s, then rebuild to about 50%. Add toward 60% after the 10-Q and the depreciation path are clear, or on a pullback toward the 10-day average. Full weight waits until $80B of construction in progress is better understood. If META gaps to 780 and we're at 35%, we'll have paid up for some shares. That's the price of insurance, and I'd pay it. Selling most of the trim now, going in at 35%, and rebuilding only on evidence is the plan that survives being wrong.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: I think we've converged more than the tone suggests. Neutral defaults to 35%, with 40% for a small position or a real tax cost and 30-35% for a core holding. Aggressive has now accepted nearly the same default. That is also my position, so the actual disagreement is small, and I'd rather spend the time on the arguments still in dispute.

First, concessions. Neutral is right that I got the sigma comparison wrong. A 10% gap up is about 0.7 to 0.8 sigma and an 18% drop is 1.2 to 1.5 sigma, so under a symmetric distribution the upside is more likely. I also accept Neutral's cap on the tax lean, and I agree it's a reason to land at 40%, not to carry more. On the ambiguous print, the ratchet argument has force. If ambiguity defaults to the structural branch, we sell after the gap without knowing why, which is the pattern we all rejected. Hold the pre-print size, don't rebuild, and let the price triggers and the 10-Q sort it out. Going in smaller also makes that rule less costly, because there is less to be wrong about while we wait.

Aggressive, I disagree with the bounded-gap argument. You say two-thirds of the move happened on ordinary days, so a full gap reversal only gets us back to 665, about 8% down. That 8% is the mild case. The trader's bad case starts at 665 and runs down to 590, so your floor is the top of the bad range. The 120-point run to 665 was also about 22% in a few weeks, and none of our data explains it either. We have no news, no sentiment and no macro for that run. "Ordinary days" means the price moves looked ordinary, not that we know what drove them. So 665 is a reference point, not a floor.

On the breakeven test, you say the extra five points need the upside to be about 1.8 times as likely as the downside, and that's roughly a wash. I accept the arithmetic, but a wash decides it in my favor. If the expected-value difference is a fraction of a point and sits inside the error of the ranges, the tiebreaker should be what the model can't get wrong. That is variance, plus the fact that we can't see the book. Neutral made your own point against you, that you can't use the 745 ceiling to justify selling and the 777 close to justify keeping 40%. If neither argument can carry the weight, size comes down to the volatility of the event, and that points to the lower end of the range.

I also don't think I was making a bearish directional call. Selling into a stretched weekly z-score before a binary print, with a primary trend still up, is a risk decision. You said 25-30% would be a bearish call on an intact trend, but size is not direction. At 30-35% we still own a third of a standard position in an uptrend that hasn't broken.

Neutral, you say the 35-versus-40 difference is under a point and a quarter in every scenario, and I agree. That is exactly why 35 is the better default. When the cost of being slightly too small is about half a point and the cost of being slightly too large is up to a point and a quarter, and the book is unknown, you take the smaller error. Your own default says the same.

On the structural-fail definition, I'd keep it narrow, as you wrote it. Capex up with margin guidance down, or G&A that recurs, means trim on the first bounce. Anything murkier means hold and wait. I'd add that the decision should come from the call detail and not the opening print, since guidance arrives with the release.

So the plan I'd stand behind is this. Check the live price first, since the data ends at the October 1 close. Sell about two-thirds of the trim at the next open, with a limit on the rest around 735-740 and a market sale around October 16 if it hasn't filled, or earlier if the earnings date is confirmed. Pick tax lots deliberately. Go in at 35% of a standard allocation, 30% if the position has grown into a core holding, and 40% if it's small or the tax cost is real. Cut toward 30% on two consecutive closes below 680.67 or one below 665. After a clean pass, with margin and capex guidance both passing and revenue growth in the 20s, rebuild to about 50% and move toward 60% after the 10-Q and the depreciation path are clear. Full weight waits until the $80B of construction in progress is better understood. An ambiguous print means hold and don't rebuild. Sentiment, news and macro get no weight, the Q3 date needs confirming, and everything applies as a percentage of whatever you actually hold.

FINAL TRANSACTION PROPOSAL: SELL

Neutral Analyst¶

Neutral Analyst: I think you two agree more than your tone suggests. Both of you say this is a trim and not an exit, and both admit the only protection against an earnings gap is the size you carry in. So the real fight is whether that size is 50% or 25-35% of a standard allocation, and neither of you has proven your number.

First, neither of you questioned the scenario ranges, and I think that's the weak spot. The good case tops out at 745, but META closed at 777.59 on September 24 and 751.66 the day after. The model says even a good print leaves the stock below where it traded a week ago. That may be right, but it means the asymmetry is partly an input, not a finding. If I back into the probabilities from the range midpoints, it looks like about two-thirds good case and one-third bad. Stretch the good case toward the recent peak and the 5.4% edge shrinks to something like 2-4%.

Conservative, you call the edge soft because it's a day and a half of ATR. But the horizon is three to four weeks, where a one-sigma move is roughly 12-15%, so the edge is about a third to a half of a standard deviation. ATR is also inflated by the gap day. It ran 20-21 before September 21. The edge is real but modest, and a modest edge argues for a modest trade.

Aggressive, I agree with your rebuttal of hold-and-let-the-stop-work, and I'm not making that argument. But your plan has the same flaw you spotted in the stop. Cutting to 25% after a failed print means selling after the gap, in the 590-665 zone, right on top of the 200 SMA near 627 and the lower Bollinger band at 587. Then you rebuild on a clean pass at higher prices. That sells low and buys high, and it can't be your protection. The 680.67 trigger is also about 2.2 pre-gap ATRs away, so there's a fair chance of tagging it on noise alone in three to four weeks. A mechanical cut there invites a whipsaw. And "keeps exposure to both" is generous, because by your own numbers the retained half has negative expected value. What you're buying is insurance against the model being wrong. That's worth something, but I don't think it's worth 50%.

Conservative, you're right about the post-gap cut. You're also right that revenue rose $13.3B while operating income fell $1.6B, that $7.7B of stock comp swamps $1.7B of free cash flow, and that 0.6x net debt to EBITDA flatters. But I'd push back in a few places.

Humility cuts both ways. We have no news, no sentiment, no macro, and no explanation for the gap. That's a reason not to assume the move reverses, just as it's a reason not to assume it holds. It argues against high conviction in either direction, which is why 25% feels too low to me.

The technicals don't look like distribution. ADX is 45, all three SuperTrends are up, OBV peaked the same day price did, and October 1 volume was the lowest of September. The 50 SMA sitting under the 200 is a lagging artifact of a fast move.

The fundamentals have an unresolved swing factor. G&A went from $2.6B to $5.6B, which is roughly five points of the ten-point quarterly margin drop. If it's a one-off accrual, underlying margin is mid-30s. If it recurs, it's a different story. We can't resolve that by arguing, which is another reason to size in the middle. Q2 free cash flow also reflects a 59% one-quarter capex jump, while operating cash flow held near $32B and trailing free cash flow is about $41B.

On hedging the retained half with options, I have no options pricing in anything we've seen. Going into a print right after an 11% gap, I'd expect the event premium to be expensive. A hedged half is economically a smaller position plus a premium, so unless there's a tax reason, I'd just sell the shares.

On "no automatic rebuild," your criteria are good and I'd adopt them. But requiring buybacks to resume is too strict, since they've been off three quarters while capex is rising. And if a clean print gaps the way September 21 did, going from 665 to 741, you'd be sitting at 25-35% waiting for a pullback that never comes.

So here's the middle path. Go into the print at about 40% of a standard allocation, in proportion to whatever you actually hold.

Tranches: Sell the first piece now. 725.93 is already inside the 720-740 zone, so there's no reason to wait for 735. Sell the second on any push toward the 744-752 area. Finish by a fixed deadline about a week before the confirmed earnings date, whatever the price. The date is still unconfirmed, so check it.
Stop: Treat a daily close below 680.67 as a review point and stop adding. Only shave to about 30-35% if it breaks together with a negative MACD histogram.
Clean pass: Define it as margin back in the mid-30s or G&A explained, capex guidance not materially above expectations, and revenue growth still in the 20s. Rebuild about half the gap within days, to roughly 60-70%. Get to full weight only after seeing the capex and depreciation path, since $80B of construction in progress is still to come.
Fail: Decide based on why it failed, not automatically at the open. If it's structural, such as capex or margin guidance, trim to 25-30% on the first bounce. If it's a one-off, hold.

A drop to about 595 costs roughly 7% of a standard allocation at 40%, versus 9% at 50% and under 5% at 25%. That feels like a loss I can absorb while keeping a seat in an uptrend that hasn't broken.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: I'll start with where the two of you have converged, because it's more than you've acknowledged. You both sell the first tranche now, drop the automatic post-gap cut, drop the options hedge, and relax the buyback requirement. You also both treat the print as an information event, not a price target. What's left is a gap of 25-30% versus 45-50%, and I think each of you is defending your number with an argument that doesn't quite hold.

Aggressive, "the less you trust the model, the closer to 50% you should stay" doesn't follow. Low trust in the model argues for sizing near the middle, hedging against being wrong in either direction. It doesn't argue for 50% specifically, which is an arbitrary point on that line. You also keep leaning on a 10% upside gap to show what trimming costs, but that scenario isn't in the trader's good case. The good case tops out at 745, so the model says you're holding the other half for a payoff outside its own range. That's a legitimate view, but then say that you're betting the model's good case is too low, instead of citing the two-thirds probability as if it supported holding. Your trend evidence also has a weak spot. ADX went from about 7 to 64 in three weeks, so what we have is one gap and one week of trend, not a mature one. The SuperTrends tell you the stock behaved well before the print. They say nothing about a G&A line that doubled or a capex guide.

Conservative, you've got the same problem from the other side. You treat missing data as if it were risk. The sentiment, news and macro reports are empty, not negative. The technical and fundamental data are rich, and the real unknown is narrow: whether the G&A jump recurs. That argues for a smaller position than standard, which we all accept, but not for a number as low as 25%. Your 545 tail is also one-sided. Yes, a full retrace costs a lot, but the stock closed at 777.59 a week ago, and a return there is 7% above today's price. If you size to the retrace, you also have to size to the re-spike. And ATR isn't a 30-point daily range. It's 26, and it was 20-21 before the gap, so the volatility argument is a bit inflated.

Your plan also has the same flaw you caught in Aggressive's. You hold 25-30% into the print, the stock gaps to 780, and you rebuild above the top of the good case, the buy-high pattern you criticized. Your rebuild bar is also close to unreachable. Requiring free cash flow back to $9-13B while capex is running at $30B means you may never rebuild into a rising stock. At that point you're not trimming a position, you're exiting it and hoping for a pullback.

My attempt at resolving this is to size the position by what the tail costs. If a 25% retrace to about 545 costs no more than 10% of a standard allocation, that gives 40%. A drop to 595 costs about 7%, and a 10% gap up earns 4%. On expected value, the model's 5.4% drag on the retained piece costs about 2.2% of an allocation at 40%, versus 2.7% at 50% and 1.4% at 25%. So the whole argument is about a point or less of expected value either way. That should lower the temperature and move the focus to execution and the post-print rules.

On execution, I'll take Conservative's point and amend mine. Sell about two-thirds of the trim now. Sell the rest on any strength through roughly 740, but with a hard calendar deadline. The Q3 date is unconfirmed, so if it isn't confirmed in the next week or so, assume a late-October report and finish around October 20. Aggressive's point about the stop review stands. A daily close below 680.67 alone is noise. Pair it with a negative MACD histogram before shaving to 30-35%.

On the rebuild, I'll tighten my own criteria after Conservative's challenge. Margin and capex guidance should both pass, not one or the other. An explained G&A line only gets you to about 36% margin, well below last year's 43%. But I'd keep revenue growth in the 20s as a requirement and not demand a free cash flow rebound, since capex is the choice here. A clean pass means rebuilding about half the gap in steps, to roughly 60%, and full weight only after the capex and depreciation path is clearer. On a fail, decide by cause. If it's structural, trim to 25-30% on the first bounce. If it's a one-off, hold.

So I still land at about 40% of a standard allocation going into the print, scaled to whatever you actually hold. If the position is already large relative to the portfolio, lean toward 30-35%. If it's small, 45% is fine.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: I think the debate has mostly done its job. You're at 30-35% and 40-45%, I'm at 40%, and by our own math the expected-value gap across that range is under a point of allocation. So I'll spend my time on the claims that still don't hold up.

Conservative, first a correction. You said I have the size rule reversed, but I don't. I said a large position leans toward 30-35% and a small one toward 45%, and you said 40% only if it's small. That's the same direction. The real difference is what to assume when we can't see the book, and there you have a fair point. If the holding is unknown, the default should sit toward the protective end. So I'll move my default to 35-40%: 40% if the position is comfortably sized, 35% if it has grown into a core holding. That costs me almost nothing.

I do still object to your tail comparison. Putting a 7% re-spike to 777 against a 25% retrace to 545 pairs a modest upside with a worst case. Pair like with like. Either it's 777 against the trader's own floor of 590, which is +7% against -18%, or it's a full retrace against a second gap-sized move up. And you have to weight by probability. Erasing six weeks of gains in one print is a low-probability event. Also, the bearish fundamentals aren't new. Q2 would have been public by about the end of July on the usual schedule, when the stock was around 540. The 31% margin, the $1.7B of free cash flow and the debt build were all known then, and the stock still ran to 777. Those facts tell you what could go wrong on the print, but they don't say the stock should return to 545. The unexplained piece is the reason for the rally, and that cuts both ways.

Aggressive, you keep saying the retained shares pay us if the model is wrong. Model error is two-sided. The ceiling of 745 may be too low, but the floor of 590 may be too high. The real finding is that the trader's ranges are narrower than the stock's normal dispersion. A one-sigma move over three to four weeks is roughly 630 to 820, and the ranges span 590 to 745. So the distribution is wider than the plan admits, with a mildly negative drift. That argues for a middle-sized position, but it doesn't pick 45-50% over 40%. Your "decide by cause on the first bounce" rule also assumes a bounce arrives. Write down now what counts as structural and what counts as one-off, so nobody improvises at the open. Structural means a capex guide up together with a margin guide down, or G&A that recurs. One-off means G&A explained and underlying margin back in the mid-30s.

Conservative, you're right that the MACD histogram filter is nearly met already, so it adds little. I'd replace it with two consecutive closes below 680.67, or one close below 665, the pre-gap close. That would mean the whole September gap is being erased, which is a real signal and not noise.

On execution, I'd make it time-based and not price-based. Sell about two-thirds of the trim now. Put a limit order on the rest near 735-740 in case strength shows up, and if it doesn't fill, sell it at market around October 16, earlier if the earnings date is confirmed sooner. That avoids both waiting for a bounce and forcing a sale into weakness.

For the rebuild after a clean pass, margin and capex guidance both have to pass and revenue growth has to stay in the 20s. Rebuild about half the gap within a few days, to roughly 50%. Add the rest, toward 60%, after the 10-Q and the depreciation path, or on a pullback toward the 10-day average, and not at the top of a gap. Full weight can wait. That answers the buy-high charge, because you're paying for information in steps and not chasing.

One thing neither of you raised is taxes. If this is a taxable account with a large embedded gain, that is a real cost of trimming and a legitimate reason to land at 45% and not 35%. If it's a sheltered account, take the lower end.

So I'll stay in the middle. Go in at about 35-40% of a standard allocation, scaled to what you actually hold, with the sizing, triggers and cause definitions fixed before the print.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We're now arguing over five points of position size, so here's what five points actually buys. Moving from 35% to 40% changes the outcome by about 0.35 points of allocation if the stock goes back to 777, 0.5 if it gaps up another 10%, 0.9 if it falls to 595, and 1.25 if it retraces to 545. Those are all under about a point and a quarter, and nobody's edge estimate is precise enough to resolve that. The rules around the sizing matter more.

Aggressive, two things. You keep saying the price already assumes a good print, but the market paid 777 for this stock a week ago on the same information. Either the market was wrong a week ago, or the trader's good-case ceiling of 745 is partly an input, as you conceded. You can't use the ceiling to justify selling and the 777 close to justify keeping 40%, because the first argument needs the model to be right and the second needs it to be wrong. The honest version is that you're hedging model error, and that is worth about 35-40%, not 45-50%. Second, the PCE point is an inference from a headline. The report says the figures weren't visible, so "the market took it fine" is weak evidence. I'd also bound the tax lean. A big embedded gain justifies a few extra points, but it shouldn't drive risk sizing past about 40%.

Conservative, your breakeven test is the argument I'd correct. You said a 10% gap up is about as rare as an 18% gap down, but that's backwards. With a one-sigma move of 12-15%, +10% is about 0.7 to 0.8 sigma and -18% is 1.2 to 1.5 sigma. The upside move is two to three times more likely under a symmetric distribution. The trader's negative drift pulls the other way, so the result is roughly a wash. That supports sitting in the middle, not at 30%.

I'd also push back on three other points. The 777-to-715 drop and the bounce to 738 are both noise. "Rejection" and "digestion" are labels we attach to one path, and neither can be known. Your "multiple expanded on information we can't see" cuts both ways, because information we can't see may be good as easily as bad. And I wouldn't default an ambiguous print to the structural branch. If the structural branch means trimming on the first bounce after a gap down, ambiguity then forces you to sell after the gap, the same sell-low pattern we all rejected. An ambiguous print should mean no rebuild and no further cut until the call detail, the 10-Q and a few sessions of price action clarify things.

My plan is as follows.

Size going in: 35% of a standard allocation as the default, since we can't see the book. Use 40% if the position is small or the tax cost is real, and 30-35% if it has grown into a core holding.
First tranche: Sell about two-thirds of the trim at the next open, since the data is as of the October 1 close. Put a limit on the rest around 735-740, and sell it at market around October 16 if it hasn't filled, or earlier if the earnings date is confirmed. When selling, pick tax lots deliberately.
Stop: Two consecutive closes below 680.67, or one close below 665, means cutting toward 30%. At this size that's a modest reduction, because it protects against a slow bleed, not an earnings gap.
Clean pass: Margin and capex guidance must both pass, with revenue growth still in the 20s. Rebuild to about 50% within days. Move toward 60% after the 10-Q and the depreciation path, or on a pullback toward the 10-day average. Full weight waits until the $80B of construction in progress is better understood.
Structural fail: That means capex up with margin guidance down, or G&A that recurs. Trim to 25-30% on the first bounce.
One-off: G&A explained and underlying margin back in the mid-30s. Hold.
Ambiguous: Hold the pre-print size and don't rebuild until the picture clears.

All of this applies as percentages of whatever you actually hold. Sentiment, news and macro get no weight, and the Q3 date still needs confirming.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We're five points apart now, so I'll skip relitigating 35 versus 40 and spend most of my time on two holes in the plan all three of us have signed onto.

First, the quick challenges. Aggressive, you rejected the ambiguity-defaults-to-structural rule because it makes us sell after the gap. Then you said the price trigger would handle a murky print, because a close under 665 cuts us toward 30%. That is selling after the gap too, just a day or two later. I proposed that trigger, so I own the problem. You also said a wash doesn't justify the lower number, but a wash doesn't justify the higher one either. The default plus the flex rules is what settles it.

Conservative, your tiebreaker is that when expected value is a wash, you take the smaller variance. That rule has no floor. Variance falls all the way to zero shares, so something else has to stop it, and what stops it is that the trend is intact on all three SuperTrend timeframes and being out is also a call. I'd also push on "the gap is most of the gain." The gap was about 76 points of a roughly 181-point move from 545, so about 42%, not most. The February insider sales were at 630 to 650 and the 200-day sits at 627, so 665 is back near where the stock spent much of the year. The first leg looks like recovery, and the gap is the genuinely new and unexplained part. Aggressive is right that 665 is a meaningful anchor, about 8% down. Conservative is right that it isn't a floor. The next reference is the 200-day, about 14% down, and 545 is below anything seen since August. That needs a severe print, not an ordinary miss.

The first hole is that the price trigger collides with the post-print rules. Say the print gaps the stock to 640. One close below 665 has then already happened mechanically, so the plan says cut toward 30% while the earnings rules say hold if it's ambiguous and trim on the first bounce if it's structural. Those can't both govern. My fix is that the two-closes-below-680.67 or one-close-below-665 trigger is a pre-print rule against a slow bleed only. Once earnings are out, the cause-based rules take over. I'd also pause price triggers for the first few sessions after the report and decide from the call detail and the guidance.

The second hole is how we've been using "percent." Our targets are percentages of a standard allocation, not of what you hold today. If someone is at 150% of standard, getting to 35% means selling far more than 60% of the position. If someone is already at 35% or less, there is nothing to sell and nothing to add. A "sell" from us only applies to the part above target. For someone at exactly 100%, getting to 35% means selling 65 points. Two-thirds of that is about 43 points at the next session and the last 22 or so by the deadline.

Execution is otherwise as we agreed, with one note. The data ends at the October 1 close and today is already October 2, so check the live price before placing anything. The deadline is a week before the confirmed earnings date, and no later than October 16 if it's still unconfirmed.

The plan, then. Go in at 35% of a standard allocation, 40% if the position is small or the tax cost is real, and 30-35% if it has grown into a core holding. Sell about two-thirds of the trim now, leave a limit at 735-740 for the rest, and sell at market at the deadline if it doesn't fill. Before the print, two closes below 680.67 or one below 665 cuts toward 30%. After the print, decide by cause. A clean pass means margin and capex guidance both hold and revenue growth stays in the 20s, so rebuild to about 50% in steps and move toward 60% after the 10-Q or on a pullback toward the 10-day. Structural means capex up with margin guidance down, or G&A that recurs, so trim to 25-30% on the first bounce. Ambiguous means hold and don't rebuild. Sentiment, news and macro get no weight, and the Q3 date still needs confirming.

This keeps most of the protection Conservative wants, since we're carrying about a third of normal size into a binary event. It keeps most of the participation Aggressive wants, since we hold a real seat in an uptrend that hasn't broken and have a defined way back in. Neither extreme needs the model to be right, and that is why I think the middle holds up.

FINAL TRANSACTION PROPOSAL: SELL

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Cut META before the Q3 print to about 35% of a standard allocation. Use 40% if the position is small or the tax cost of selling is real, and 30% if it has grown into a core holding. Check the live price first, since the data ends at the 10/1 close of 725.93. Sell about two-thirds of the trim at the next session. Put a limit at 735-740 on the rest, and sell it at market by October 16, or a week before the confirmed earnings date if that comes sooner. Add nothing above 700. Before the print, two closes below 680.67 or one close below 665 means cutting to about 30%. After the print, act on the cause, not the opening price: on a clean pass rebuild to about 50%, then about 60%; on a structural fail trim to 25-30% on the first bounce; on an ambiguous print hold. All percentages apply to your own holding; if you are already at or below target, do nothing.

Investment Thesis: DECISION: Trim, not exit. All three risk analysts and the trader ended at SELL as a trim. The only open question was how much to keep, and the plausible range was 35-50% of a standard allocation. I chose 35% as the default.

1) THE PRICE ASSUMES A GOOD PRINT. In the trader's scenarios, the good case is worth 688-745 (about 20x on about $96B EBIT at a 35% margin) and the bad case 590-665. Expected value is about 686.50 (0.5x745 + 0.5x628), about 5.4% below 725.93. A holder at 726 gains about 2.6% on a pass and loses about 13.5% on a fail, so keeping full size breaks even only if a pass is about 84% likely. Nobody claimed that kind of edge.

2) THE FUNDAMENTALS ARE A REAL RISK INTO THE PRINT. - Q2 operating margin fell to 30.9%, from 43.0% a year earlier and 40.6% in Q1. - Revenue rose $13.3B year over year while operating income fell $1.6B. - G&A more than doubled, from $2.6B to $5.6B, with no explanation. That is about half of the margin drop. - Q2 free cash flow was $1.7B, against $30.1B of capex and $7.7B of stock compensation. Buybacks have been zero for three quarters. - $80.3B of construction in progress has not started depreciating yet. - The balance sheet is not the problem. The fundamentals report's $68.2B net debt is wrong: $112.3B of debt minus $90.3B of cash and investments is about $22B, roughly 0.2x EBITDA.

3) THE TECHNICALS SAY TRIM, NOT EXIT. The primary trend is up on weekly, monthly and daily SuperTrend, OBV confirmed the rally, and price is far above the 50 and 200 SMAs. That rules out a full exit. But the advance looks late and is cooling: - Weekly z-score is +2.00 and the weekly TD-9 count is at 6. - ADX fell from 64 to 46 and the MACD histogram is only +0.80. - About 42% of the rally since 545 came from the unexplained 11.4% gap on 9/21.

4) WHY 35% AND NOT 50%. The bear case won the direction. On size, the Conservative analyst's tiebreak decided it, and the Neutral analyst's math supports it: - Between 35% and 50%, expected value differs by about a point of allocation or less, which is within the error of the scenario ranges. - The downside tail is larger: 595 is about -18% and 545 is about -25%, against about +7% back to 777. - A stop cannot protect against an earnings gap, so position size is the only real control. - We cannot see the caller's book. The Aggressive analyst made a fair point: the 745 ceiling sits below where the stock closed a week earlier, so it is partly an assumption. That argues for keeping a real stake rather than going to 25%, not for keeping 50%.

5) RULES (from the Neutral analyst's final version). - The price triggers apply only before the print. Pause them for a few sessions after the report. - Clean pass: margin and capex guidance both pass and revenue growth stays in the 20s. Rebuild to about 50% in steps. Go toward 60% after the 10-Q, or on a pullback to the 10-day average. Do not rebuild at the top of a gap. - Structural fail: capex guidance up with margin guidance down, or G&A turns out to recur. - Ambiguous print: hold and do not rebuild. This avoids selling after the gap.

WHAT WOULD CHANGE THIS. - To Hold or Overweight: the 10-Q shows the G&A jump was a one-off and non-G&A operating cost growth is slowing, or Q3 operating income is about $22B or more with positive FCF. - To Sell: G&A recurs, capex guidance rises while margin guidance falls, or operating income comes in below about $20B.

PRICE TARGET: 686.50 is the probability-weighted value of the trader's scenarios (good-case top 745 and bad-case midpoint about 628 at equal odds). It is backed up technically by the Bollinger middle band at 689.77 and sits between the 680.67 daily SuperTrend line and the 713 low.

DATA GAPS: We don't know what caused the 9/21 gap, what is in the G&A jump, where roughly $24B of cash went, or the confirmed Q3 date. The sentiment, news and macro feeds were empty and got no weight, and the valuation multiples are the analyst's estimates, not vendor data.

Current Price: 725.93

Price Target: 686.5

Confidence: Medium

Time Horizon: 1-2 months (through the Q3 FY2026 report, expected late October)